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1.1. Stress in general  
Each living organism continuously struggle to maintain an internal homeostasis, as it 
was first defined by Walter Cannon [1]. Homeostasis is an equilibrium condition for many 
different physiological variables: body temperature, ionic composition and osmolality, 
pH, and blood glucose level etc. For survival in a continuously changing external and 
internal environment, these variables should be kept in well-defined range [2]. In 1936, 
Hans Selye published a paper in Nature entitled “A syndrome produced by diverse 
nocuous agents” and introduced the stress concept. He wrote: “…if the organism is 
severely damaged by acute non-specific nocuous agents, a typical syndrome appears, the 
symptoms of which are independent of the nature of the damaging agent, and represent 
rather a response to damage as such” [3]. He noticed that the same pathological triad 
(adrenal gland enlargement, thymus involution, gastrointestinal ulceration) evolves in 
response to many different stressors (bacterial infection, toxins, physical stimuli) [3]. A 
few years later, Selye defined the General Adaptation Syndrome, GAS as an “integrated 
syndrome of closely inter-related adaptive reactions to non-specific stress itself“ [4]. 
GAS develops in three successive stages: 1. alarm reaction, 2. active resistance, 3. 
exhaustion (Fig. 1.) [5].  
 





Sterling and Eyer were the first, who introduced the expression allostasis, which 
basically the maintenance of homeostasis through changes. The expended energy for 
allostasis is the allostatic load [6].  
In response to various external and internal stressors catecholamines release from 
adrenal medulla, induced by the activation of sympathetic nervous system (SNS), and the 
hypothalamo-pituitary-adrenocortical (HPA) axis became rapidly activated. [7]. In 
response to the activation of both sympathetic nervous system and HPA, bodily resources 
are mobilized for fight or flight, including centrally mediated cardiovascular adaptations 
with increased heart rate and blood pressure and redistribution of blood supply between 
muscles and skin. During acute stress, respiration is also increased to support increased 
metabolic demands with oxygen. Increased vigilance, alertness and arousal are also 
specific features of stress. [8]. From the pathophysiological point of view, it is important 
to distinguish between acute and chronic stress. Acute stress is a short term challenge, 
while during chronic stress the body is exposed to stressors for a prolonged time or 
frequently exposed to various different stressors, chronically [9].   
 
1.2. Hypothalamo-pituitary-adrenocortical (HPA) axis 
Different environmental stimuli trigger stress response and activate the 
neuroendocrine stress axis as a reflex regulation. In first step, corticotropin-releasing 
hormone (CRH) and vasopressin (AVP) are released from the parvocellular neurons of 
the hypothalamic paraventricular nucleus (PVN). These hormones are secreted to the 
hypophyseal portal circulation and trigger adrenocorticotropic hormone (ACTH) release 
from the adrenocorticotropic cells of anterior pituitary gland. Then, ACTH reaches the 
adrenal cortex via the blood circulation and stimulates cortisol (in human) and 
corticosterone (in rodents) release from the zona fasciculata. Corticosteroids act through 
mineralocorticoid (MR) and glucocorticoid (GR) nuclear receptors [10]. The basal 
occupancy of MR is around nine fold higher than GR; because affinity of MR is higher 
(Kd = 0.1–0.5 nM) for corticosterone than that of GR (Kd = 2–5 nM). For this reason, 
occupancy of GR is increased seven-fold higher during stress, while MRs are alre ady 
fully occupied even at no stress conditions [11]. Therefore, stress effects occur rather 
through GR than MR. MR is involved in the appraisal process and the early-phase of 
stress [10]. Inhibitory feedback by glucocorticoids plays a major role in stress response. 




extrahypothalamic sites (hippocampus, cortex) and inhibit expression of effector 
molecules [12].  
The neural regulation of HPA axis is originated from different brain regions, which 
depends on the nature and intensity of stressor. The information of physical and metabolic 
stressors (hypovolemia, hypoglycaemia) are transported through ascending neurons from 
the brainstem and spinal cord and these neurons have direct projection to the PVN. These 
projections originated from the nucleus of the solitary tract (NTS) and C1 and C3 
catecholaminergic neurons. Brainstem pathways also interact with other structures such 
as dorsal raphe and dorsomedial hypothalamic nucleus (DMH) [10].  
By contrast, psychogenic stressors require more complex polysynapthic pathways, 
which include limibic brain regions such as prefrontal cortex (PFC), hippocampus, 
amygdala and bed nucleus of stria terminals (BNST). PFC projects both inhibitory and 
stimulatory information to PVN. These inputs are mediated through interconnections with 
other structures such as hippocampus, ventral subiculum (vSbc) and amygdala. The 
hippocampus is mainly suppress the activation of HPA axis. The projection of 
hippocampus reach indirectly the PVN. The projection occurs via vSbc and PFC. These 
regions innervate the periventricular region that projects glutamatergic and GABAergic 
neurons to the CRH neurons. There are neuronal innervations as well as from basolateral 
and medial amygdala to the PVN that potentiate the HPA axis. The central nucleus of 
amygdala express also CRH and has essential role in the stress induce behavioural 
responses (especially fear). The BNST is an integrative centre between limbic brain 
regions and PVN. The projections of BNST innervates the periventricular GABA- and 
glutamatergic neurons and suppress the inhibiting signals of GABAergic interneurons 
[10].   
 
1.3. Central regulation of food intake and energy metabolism 
In the beginning of this chapter, I would like to clarify few metabolism related 
concepts for the better understand ability. Orexigen is any substance, which stimulates 
appetite; by contrast, anorexigen inhibits appetite. Catabolism is the set of metabolic 
pathways that breaks down molecules into smaller units and anabolism constructs 
molecules from smaller units.  
To govern neuroendocrine autonomic and behvaioral stress responses, hypothalamus 




nucleus of the hypothalamus (PVH), ventromedial nucleus (VMH) and lateral 
hypothalamic area (LHA) were described as a key feeding regulatory centers in the 
hypothalamus [14]. Circulating metabolic-related hormones mediate information to these 
centers about the energy status from periphery. These hormones bind to specific receptors 
and can alter the physiology of the receptor containing neurons. Leptin, insulin and 
ghrelin all target multiple brain neurons involved in energy intake [15-17].  
Leptin is secreted by adipocytes and secreted in proportions of adipose depots. The 
hormone has a key role in the regulation of glucose and lipid metabolism, by suppressing 
food intake by decreasing meal size rather than meal number [18-20]. In particular, leptin 
receptor (LepR) expressed in the retrochiasmatic area, arcuate- (ARC), dorsomedial- 
(DMH), ventral premammillary- (PMv) and ventromedial (VMH) nuclei of the 
hypothalamus. Elias et al. examined neuronal activation after leptin administration [21]. 
Leptin-induced c-Fos expression was detected in Lepr-expressing neurons in the 
hypothalamus and hindbrain [21]. In addition, other studies demonstrated that fos 
expression was very low in PVH, unlike in ARC and DMH, because of the secondary 
activation of leptin-dependent pathways [22, 23].In addition, leptin also aim hindbrain 
and the midbrain ventral tegmental area (VTA) to affect the reward system. Following 
studies showed that dopamine is an important neurotransmitter in this influence because 
of the dopaminergic inputs to the nucleus accumbens (NAc) from VTA [24-26]. LepR 
expressed also in the medial part of the nucleus of the solitary tract (NTS) and expression 
of leptin activation marker (pSTAT3) was demonstrated in this brain region after leptin 
injection [27].  
Insulin is able to reduce blood glucose concentrations by facilitating glucose uptake 
into muscle, liver and adipose tissue through insulin dependent glucose transporter 
protein GLUT4. The hormone is secreted by the β cells of Langerhans islets of pancreas 
[28]. Insulin enters the brain from blood circulation [29] and reduces food intake there by 
suppressing neuropeptide Y (NPY) and increases the activation of melanocyte stimulating 
hormone (α-MSH) neurons in ARC [30]. Insulin also able to alter reward and motivation 
processes through insulin receptors (IRs) in the limbic system [31, 32]. In addition, insulin 
reduces the meal size by promoting the effect of cholecystokinin (CCK) [33]. It is also 
secreted at the proportion of adipose tissue [34]. Insulin receptors (IR) are expressed in 
different locations of the brain: olfactory bulb, cerebellum, parts of the cortex, 




hypothalamus is in the focus of investigation of insulin’s action in the aspect of metabolic 
function [36]. 
Ghrelin is a gastrointestinal (GI) hormone, which induces food intake. It is secreted by 
the stomach and proximal small intestine [37]. The ghrelin receptor (GHSR1) belongs to 
the G-protein coupled receptor family and affects adenylate cyclase activity and 
intracellular Ca2+ channels. GHSR1 expressed in most of the brain regions where IR or 
LepR are found [17]. Ghrelin also influences glucose homeostasis and reward [37].  
Pancreatic Peptide YY3-36 (PYY) and Glucagon-Like Peptide 1 (GLP-1) are secreted 
by L cells in the distal part of small intestine. Both hormone inhibit food intake but on 
different ways. PYY binds Y2 receptor in the ARC and regulates energy homeostasis. In 
contrast, GLP-1 enhances the secretion of insulin but has direct effect on vagal afferents 
[38-40]. 
Cholecystokinin (CCK) is synthesized by I cells in the proximal part of intestine. The 
hormone regulates metabolism via vagal nerve and hindbrain. It has a powerful effect to 
decrease meal size [41]. 
Arcuate nucleus ARC harbors two separate neuron population that exert opposite 
influence on food intake (Fig. 2.). Neuropeptide Y (NPY) and Agouti-related peptide 
(AgRP) colocalized neurons mediate anabolic effects. These neurons located in the 
medial portion of ARC and the cells are GABAergic [42]. Intracerebroventricular 
administration of NPY or direct injection into hypothalamus stimulates food intake and 
reduce energy metabolism. Consequently, continuous central dosage of NPY leads to 
obesity [43, 44], however, NPY–KO mice display normal food intake and normal leptin 
and insulin levels [45]. It is likely that other orexigenic neuropeptides, such as AgRP, 
orexin or melanin-concentrating hormone (MCH), may compensate the lack of NPY. 
Orexin and MCH are expressed in the lateral hypothalamic area and adjust food intake to 
the arousal state [46, 47]. NPY expressing neurons are key mediators of the orexigenic 
effect of ghrelin while they are inhibited by leptin and insulin. In addition, NPY/ AgRP 
neurons project a tonic GABAergic inhibition to the anorexigenic proopiomelanocortin 
(POMC)/ cocaine- and amphetamine-regulated transcript (CART) neurons [48].  
The other major metabolic-related neuron population in the ARC is anorexigenic. 
These cells are located in the lateral part of the nucleus and express POMC (alpha-
melanocyte-stimulating hormone (MSH) and CART. Neurons in this region are equipped 
with leptin and insulin receptors and mediate their anorexigenic effect by increasing 




coexpressed rather in orexigenic NPY/AgRP neurons than POMC neurons in human [50]. 
Besides that, CART is translated with MCH in the lateral hypothalamus in several species 
[51].  
The anorexigenic effect of POMC neurons in ARC projects to PVN, ventromedial 
nucleus and lateral hypothalamus and reduce food intake with increased energy 
expenditure (EE) [52]. Similarly, NPY/AgRP neurons of ARC project to the same 
hypothalamic regions (PVN, VMH, LH) as POMC neurons, however orexigenic neurons 
of arcuate nucleus send axons also to the dorsomedial nuclei of hypothalamus. In these 
nuclei (PVN, VMH, LH, DMH), NPY neurons affect on the contrary of POMC food 
intake and EE via Y1,2 and 5 receptors; while, AgRP alters energy homeostasis as an 
antagonist of melanocortin 4 receptor (MC4R), thus inhibit the effect of α-MSH [50, 53]. 
The projected information of arcuate nucleus influences the parvo- and parvicellular 
neurons of PVN, where different hormones are expressed, such as corticotrophin-
releasing hormone (CRH), thyrotrophin-releasing hormone (TRH) and oxytocin, thus 
regulates different neuroendocrine pathways [54].  
Huge number of VMH are glucose-responsive neurons, which mediate the 
anorexigenic effect of leptin [55]. These neurons are also intervened by POMC neurons 
of ARC and mediate the effect of leptin-induced anorexia partly to the PVN via brain-





Figure 2. Schematic representation of metabolic regulation in arcuate nuclei of the 
hypothalamus [57]. 
 
The dorsomedial nucleus is received inputs from other hypothalamic areas which are 
involved in food intake regulation. Furthermore, DMH interconnected with the circadian 
centre, suprachiasmatic nuclei (SCh) and includes neurons, which express circadian 
genes, sensitive to the daily schedule [58]. DMH intervenes preoptic area (POA), PVN 
and LH. Therefore, different studies propose that DMH plays an essential role in the 
circadian effect of thermoregulation, endocrine function, arousal and food intake [59], 
however, some studies disagree this hypothesis [58].  
 
1.4. Effect of stress on the metabolic system 
Stress is accompanied with increased energy expenditure and metabolic rate to 
promote coping. Food intake and appetite is inhibited during acute stress, which 




hormones, - the glucocorticoids and catecholamines (adrenaline and noradrenaline) - have 
profound metabolic effects. Epinephrine is synthetized in the adrenal medulla of adrenal 
gland by the chromaffin cells. These cells have sympathetic innervation and release upon 
sympathetic stimuli. Epinephrine is rapid mediator of stress response and acts on nearly 
all body tissues. Stress is accompanied with a rapid elevation of blood glucose, which is 
regulated by adrenaline. At cellular level, adrenaline phosphorylates enzymes of 
glycogenolysis in the liver and muscle, which results glycogen conversion to glucose. 
Furthermore, adrenaline has an indirect effect on blood glucose level by triggering 
glucagon release and inhibiting insulin secretion. In the adipose tissues, adrenaline 
activates lipolysis [60].  
Glucocorticoids are steroid hormones, which released from the zona fasciculata of 
adrenal cortex to the stress-induced activation of HPA axis. Glucocorticoids increase 
blood glucose level by increasing the synthesis of gluconeogenesis enzymes. The 
hormone mobilizes also the substrates for gluconeogenesis from other tissues via 
mobilization of amino acids from extrahepatic tissues and stimulates lipolysis in adipose 
tissues. In addition, these steroid hormones decrease energy uptake in muscle and adipose 
tissues to inhibit energy storage [61]. The effects of glucocorticoids are relatively slow, 
compared to other metabolic hormones like insulin, leptin or catecholamines, because 
these changes mediated through gene expression rather than direct control of enzymes 
regulation [62]. In addition, significant level of GRs are localized in different brain 
regions that influencing metabolic system, such as ARC, VMH and PVH [61]. 
The permanent presence of stressors seriously affect the resistance of the body, 
therefore the energy homeostasis may collapse during prolonged chronic stress. Catabolic 
changes may dominate in response to high level of glucocorticoids. Furthermore, due to 
the chronically elevated blood glucose level results in increased insulin secretion, which 
leads to insulin resistance and type2 diabetes on the long run [63]. Besides that, hormone 
sensitive lipase is continuously activated during chronic stress, which elevates glycerine 
and fatty acid levels in the blood and these changes accompanied with other metabolic 
related maladaptive processes like hypertriglyceridemia, non-alcoholic fatty liver disease 
(NAFLD) or atherosclerosis [64]. 
The sympathetic nervous system and glucocorticoid hormones act together to alter central 
metabolic pathways. Sympathetic activation results in suppression of food intake by 
inhibiting orexigenic NPY action [65]. In addition, α-MSH neurons of ARC potentiate 




expression and results in activation of sympathetic preganglionic neurons projecting the 
brain stem and spinal cord. Leptin also inhibits NPY neurons in ARC, and activates the 
ventro- and dorsomedial hypothalamic projection of PVN [66]. 
1.5. Effect of stress on gastrointestinal tract (GI) 
It is well known, that symptoms of different GI disorders worsen in prolonged stress 
and negative emotions. Activation of HPA axis and sympathoadrenal system alter various 
physiological functions of GI such as gastric secretion, gut motility, visceral sensitivity, 
mucosal blood flow, barrier function and triggers different gastrointestinal relevant 
symptoms like dyspepsia, diarrhoea or abdominal pain. Chronic activation of the stress 
system can lead to severe GI disorders such as irritable bowel syndrome (IBS) or 
inflammatory bowel disease (IBD). Enteric nervous system (ENS) plays an essential role 
in the regulation of gut functions. It has a great impact on motility and secretion of GI 
neuropeptides and hormones. Strong evidences confirm that, prolonged stress as well as 
early life stress are able to alter central pain circuitry, influence motility and permeability 
through GI [67, 68]. 
In the last decade, emerging studies demonstrated important interaction between the 
gut microbiome and host. Stress induces a notable shift in the composition of microbiota, 
with the growth of pathogenic bacteria and this alteration further aggravate the symptoms 
of GI disorders. For example, norepinephrine enhances the virulence of E. coli or C. jejuni 
[67, 68]. Infants with altered microbiota composition showed higher level of infant GI 
symptoms and allergic reactions. 
The gut microbiome able to modify the interaction between HPA axis and immune 
system. Stress increases gut permeability and results in “leaky gut” which underpins 
chronic low-grade inflammation, due to the elevated plasma level of bacterial 
lipopolysaccharide (LPS) [69]. CRF, which is also produced within the gut, plays an 
essential role in the stress-induced gut permeability dysfunction, modulation of 
inflammation in gut, and contributes to visceral hypersensitivity via CRF receptors. Of 
note, early life stress causes elevated plasma corticosterone level and results in increased 
gut permeability and bacterial translocation to spleen and liver [69]. 
1.6. Gut brain axis 
The microbiome is a complex and dynamic mixture of microorganisms, which 




present in different parts of the human body such as the oro-naso-pharyngeal cavity, skin, 
vagina, gastrointestinal tract etc. These communities interact with host and influence 
health and disease [71]. The largest proportion of the microbiome is found in the 
gastrointestinal tract: from the stomach to the colon, bacterial biomass ranges from 102–3 
to 1011–1012 cells/ml, among those approximately 95% being anaerobic [70]. The human 
gut microbiome consists of seven major phyla: Bacteroidetes, Actinobacteria, 
Cyanobacteria, Fusobacteria, Proteobacteria, and Verrucomicrobia [72]. The 
microbiome is exposed to different factors, which constantly change the composition of 
it. These factors include many variables such as birth, breast feeding, diet, stress, aging, 
drugs (antibiotics) etc. [73-75].  
Gut microbiome widely interacts with the host’s metabolic system (Fig.3.). The dietary 
ingredients can be metabolized differentially and it highly depend on the composition of 
microbiome. For instance, different bacteria can produce bile acid, short chain fatty acids 
(SCFA), choline etc. [69, 76]. SCFAs suppress histone deacetylases and able to modify 
intracellular signalling through their specific receptors that found throughout the body. 
For instance, propionic acid mediates advantageous effect on the regulation of body 
weight and glucose metabolism by influencing FFAR3 receptor containing nerve fibres 
in hepatic portal vein [77]. Recent studies indicate that microbiome is able to influence 
enteroendocrine cells in gut. E. coli produced proteins are able to induce secretion of 
GLP-1 and PYY hormones from enteroendocrine cells that affect food intake [78]. For 
these reason, microbiome can contribute to the development of different metabolic 





Figure 3. Schematic representation of different pathways of gut brain axis [81].  
 
It is also well documented that a shift in gut microbiome can be associated with 
gastrointestinal disorders such as inflammatory bowel disease (IBD) and irritable bowel 
syndrome (IBS). A recent study identified key bacterial species that may be involved in 
the development of these gastrointestinal diseases and altering the gut microbiota has 
been proposed as a strategy for the treatment [82]. 
Growing body of evidence indicates dysbiosis of gut microbiota could contribute or, 
exaggerate several neuropsychiatric disorders such as anxiety, depression, Alzheimer 
disease, Parkinson disease, multiple sclerosis, autism etc. [75]. There are many different 
pathways, through which, microbiome can influence the normal function of brain. 
Recently, a number of microbial metabolites (referred to as neuro-active metabolites) 
produced through tryptophan metabolism have been suggested to influence the gut brain-
axis. Interestingly, germ free mice have elevated level of circulating tryptophan beside 
lower level of 5-HT compared to conventionally colonized mice. Another study indicated 
that probiotic administration of Lactobacillus decreased the colonic tryptophan 
degradation by inhibiting indoleamine 2,3 dioxygenase (IDO – rate limiting enzyme of 




neurometabolites such as GABA, noradrenaline, serotonin, dopamine, acetylcholine, 
tryptophan that could directly affect brain functions [76]. In addition, gram-negative 
bacteria induce pro-inflammatory cytokines by their cell wall component, LPS; which 
stimulates toll- like receptor (TLR) coupled immunological pathways. Inflammatory 
mediators can also access to the brain. For instance, Campylobacter jejuni infection 
triggers neuronal activity in the vagal sensory ganglia and in the NTS. The vagus nerve 
has also an important role in the mediation of gut-brain communication. There are strong 
evidences, which demonstrate that microbiome is capable to alter the activity of vagal 
projection. Administration of Lactobacillus reuteri supported wound healing in mice by 
enhanced oxytocin secretion in hypothalamus, which was eliminated by vagotomy. 
Another experiment showed that administration of Lactobacillus rhamnosus induced 
anxiolytic and antidepressant-like behaviour, however, this effect was attenuated in 
vagotomized mice [69, 76]. 
 
1.7. Targeting the microbiome 
As microbiome is a permanently changing community and the effects of microbiome 
on the host depend on which bacteria colonized the host’s gut. Although the composition 
of the gut microbiome is relatively constant, it can be targeted by different factors, which 
provide the basis of microbiota- based therapies. [75]. There are specific dietary 
supplements through which the microbiome can be targeted. These are the probiotics, 
prebiotics and synbiotics.  
Probiotics are living microorganisms, which provide beneficial effects to the host. 
Probiotics should survive the low pH in the stomach, biliary salts and should be able to 
colonise the gut [69]. The most popular probiotics belong to Lactobacilli and 
Bifidobaceria, however, yeasts, such as Saccharomyces boulardii are also used in 
probiotic preparations. 
Prebiotics are also a manuipulating factor, which are non-digestible fibres. These 
fibres are selectively metabolized in the intestinal tract and as a result, promote the 
proliferation of beneficial bacteria. For example, a Bifidobacterium derived prebiotic (B-
GOS) induced bifidogenic effect in microbiome of young volunteers [69].  
Parabiotics are non-living, inactivated probiotics, but imitate the beneficial effect of 
the living microorganism. In the contrary of probiotics, parabiotics have some advantages 




possibility of inflammatory responses are lower that may occur in individuals with weak 
immune system [84]. 
Postbiotics are water-soluble metabolites, which are metabolized by gut colonising 
bacteria. Postbiotics includes wide range of metabolites such as enzymes, proteins, 
peptides, saccharides, organic acid, SCFA etc. It is demonstrated, postbiotics can mimics 
the effects of probiotics without the risky inherent [84].  
Antibiotics is an antimicrobial molecule, which inhibit the growth of bacteria. In case 
of bacterial infections, antibiotics are the primary agents of pharmacological defence. 
They target pathogenic bacteria, however, administration of antibiotics have also harmful 
effect on commensal bacteria in the gut and result reduced amount of microbiome and 
microbial diversity [69]. 
Faecal microbiota transplant (FMT) is a recently used administration. As it implies, 
FMT is a transplantation of faecal bacteria from healthy donor to a recipient. FMT was 
applied first in clinical trial against Clostridioides difficile infection and the treatment was 
highly effective against the infection. In addition, FMT is widely used application against 






















My first aim was to investigate the effect of stress on the metabolic system. Therefore, 
I raised the following specific questions: 
 How an acute restraint stress affects metabolic variables and locomotor 
behavior? 
 What is the role of the hypothalamic paraventricular nucleus in the 
regulation of metabolic- and behavioral changes?  
 What are the differences between metabolic changes seen in response to 
acute and chronic stress?  
How the metabolic system recovers after repeated stress?  
 
My second main aim was to test the hypothesis, whether rifaximin – non-absorbable 
antibiotic - restores chronic stress-induced gastrointestinal and inflammatory symptoms 
and changes in microbiome along with stress-induced changes in anxiety-like behaviour.  
Third, we challenged the hypothesis if there is a relation between the systemic 


















3. Materials and methods 
3.1. Animals 
All experiments were performed on male mice with C57BL/6J genetic background. 
CRH-Ires-Cre transgenic mouse line was used in the virus-injected experiments. Animals 
were born and housed at the minimal disease (MD) level of Medical Gene Technology 
Unit at the Institute of Experimental Medicine. Mice were housed in 12 h light/dark cycle 
(lights on from 6 a.m. to 6 p.m.) at 21–22 °C with humidity. Animals received standard 
pelleted rodent chow (VRF1, Special Diets Services (SDS), Witham, Essex, UK) 
containing 19,1 g% protein, 55,3 g% carbohydrate and 4,8 g% fat. Chow and water were 
provided ad libitum. Experiments were complied with the ARRIVE guidelines and 
performed in accordance with the guidelines of European Communities Council Directive 
(86/609 EEC), EU Directive (2010/63/EU) and the Hungarian Act of Animal Care and 
Experimentation (1998; XXVIII, Sect. 243/1998). All procedures and experiments were 
approved by the Animal Care and Use Committee of the Institute of Experimental 
Medicine (permit number: PEI/001/29-4/2013). 
3.2. Stereotaxic surgery 
CRH-IRES-Cre transgenic mice were anesthetized with a cocktail of 100 mg/kg 
ketamine and 10 mg/kg xylazine (1 ml/100 g bw, i.p.). Bilateral stereotaxic injection of a 
virus vector construct (pAAV8/hSyn-DIO-hM3D(Gq)-mCherry, Addgene; 4-7,9 x 
1012/ml, UNC GTC Vectore Core) was performed into both side of paraventricular 
nucleus (PVN) (30 nl/side). PVN was approached by a glass cannula at the following 
coordinates from Bregma: AP:-0,7mm; lat: -0,035mm DV: -0,5mm. After surgery, mice 
recovered for 3 weeks before the beginning of metabolic measurements. Control animals 
have been injected with pAAV-hSyn-DIO-mCherry.  
3.3. Stress procedures 
3.3.1. Acute and repeated stress 
Mice were exposed to restraint acute stress for 1h (n=8). For the procedure, 50ml 
Falcon tubes were used with small holes on side and one at the end for breathing and 
ventilating. Tubes were filled with paper towel from the opening of tube and closed with 




being harmful and provided a stressful event. During the 1h, tubes were stabilized from 
outside. Experimental design and timeline diagram is shown on figure 4. 
 
Figure 4. Overview of the acute stress experiment. 
 
3.3.2. Chronic variable stress (CVS) 
During CVS, experimental animals were stressed for 4 weeks, two times daily, by 
different psychogenic stressors: 
 Water avoidance stress (WAS) – The test apparatus was a plastic tank (40 cm 
length × 40 cm width × 30 cm height) with a fixed glass cylinder (d=8 cm) in the 
center of the floor. The tank was filled with fresh water to 1 cm below the top of 
block. The stressed mice were placed on the block for 1 h. 
 Disturbed circadian rhythm - Mice were exposed to changed or extended light or 
dark phase. 
 Social defeat – Experimental mice (intruder) were placed one by one into the 
home cage of dominant CD1 male mice (aggressor) and they were left there for 8 
minutes. 
 Footshock - Mice were shocked in every 20 sec by 0,5 mA electric shock for 12 
minutes. 
 Forced swim - Mice were forced to swim for 6 min in 18 cm high and 14 cm 
diameter glass cylinders filled with clean tap water. 
 Slanted cage – The home cage of experimental mice was tilted to a 45° angle 
 Soaked bed – The bedding was mixed with water in the home cage 
 Shaking – The cages of the mice were placed on a shaker for 1 hour. The shaking 




 Crowding – The moving area of the mice was reduced and the experimental mice 
were crowded. In case of rifaximin experiment, vehicle and rifaximin treated mice 
were separately crowded. 
 Rat feces odour – Feces of male rats was collected and it was placed into a Falcon 
tube with small holes and the tube was placed into the home cage of the stressed 
mice. 
Daily schedule of the stressors is found in table 1. After CVS procedure, a cohort of 
experimental animals (n=4/group) were transferred to cages of Phenomaster system for 
metabolic measurements. Open field test was done with another cohort of mice (n=5-
6/group), then they were sacrificed, blood was collected on EDTA and plasma was stored 
at -20°C until assays. Adrenal glands were dissected and measured after autopsy. 
Experimental design and timeline diagram is shown on figure 5. 
 
Figure 5. Overview of the chronic variable stress experiment.  


















Table 1. Daily schedule of the chronic variable stress. 
CVS protocol 
day a.m. p.m. 
1.day water avoidance overnight light 
2.day social defeat footshock 
3.day forced swimming soaked bedding + slanted cages 
4.day crowding + shaking crowding + dark for 18h 
5.day restraint isolation 
6.day social defeat forced swimming 
7.day crowding + shaking soaked bedding + slanted cages 
8.day forced swimming footshock 
9.day water avoidance overnight light 
10.day social defeat footshock 
11.day isolation + rat feces odour 
isolation + rat feces odour + dark 
for 18h 
12.day crowding + shaking 
crowding + soaked bedding + 
slanted cages 
13.day forced swimming forced swimming 
14.day social defeat restraint 
15.day rat feces odour + dark for 18h 
crowding + shaking + overnight 
light 
16.day isolation + rat feces odour footshock 
17.day forced swimming crowding + soaked bedding 
18.day social defeat (6-10 min) 
isolation + rat feces odour + dark 
for 18h 
19.day water avoidance footshock 
20.day dark for 18h crowding+shaking 
21.day 
crowding + soaked bedding + slanted 
cages 
isolation + rat feces odour 
22.day footshock forced swimming 
23.day water avoidance overnight light 
24.day crowding + shaking 
isolation + rat feces odour + dark 
for 18h 
25.day social defeat slanted cages + soaked bedding 
26.day footshock restraint + shaking 
 
3.3.3. Two-hits stress protocol  
This protocol is a frequently used procedure to induce anxiety or depression-like 
symptoms in experimental animals [87]. It started at postnatal day 1, when pups were 
separated from their mother (maternal separation MS) for 3 hours daily for 12 days (early 
life stress - first hit). During the three hours, mothers were placed into separate individual 




(30-33°C). Mothers and pups were in two separate rooms. Control litters were not 
separated and left undisturbed except the change of bedding once a week. Pups were 
weaned at the 21th day after born and they were housed 2-3/cages. At the age of 50 days, 
mice were exposed to chronic variable stress paradigm (CVS - second hit). The protocol 
followed the same CVS schedule, which is written in table 1.  
 
3.4. General procedure in rifaximin experiment 
During chronic variable stress, half of the animals received 300 mg/kg bw/day 
rifaximin, a non-absorbable antibiotic (Sigma). Animals from different litters were 
randomly assigned to rifaximin/vehicle groups. Rifaximin was dissolved in 5% 
hypromellose solution in drinking water. The other half of mice (controls) received 5% 
hypromellose to drink. Fluid intake and body weight of the animals was monitored and 
rifaximin concentration in the drinking water was adjusted. This experiment was 
performed on two different set of experimental mice. At the end of the experiment 
behaviour tests were performed on both sets (see below). After last test, one set of mice 
(n=5-7/groups) was decapitated (30 min after EPM) and trunk blood was collected on 
EDTA and plasma stored at -20°C. This blood sample was the measure of stress-induced 
CORT, as it was collected at the time of maximal adrenocortical CORT release provoked 
by EPM exposure. Adrenal glands and thymus were collected, cleaned and weighed for 
each mouse. Organ weights were normalized to final body weight and expressed as mg/g 
bw. Colon, liver, mesenteric lymph node and colon content were harvested and stored at 
-70°C until assay. The upper intestinal tract has a very low population of bacteria because 
of different factors like gastric acidity, propulsive motility and pancreatic enzymes. By 
contrast, the colon has a very stagnant motility with retropulsive contractions keeping the 
contents in the proximal colon and thus, the largest and “most constant” bacterial 
ecosystem located in the colon [88]. For this reason, colon tissue and content was used 
for further analysis. Experimental design and timeline diagram is shown on figure 6. The 
second set of mice (n=22) were exposed to gut permeability test after the last behavioural 





Figure 6. Overview of the rifaximin experiment.  
MS: Maternal separation (3h daily); CVS: Chronic variable stress (2x daily); OF: Open 
field test; EPM: Elevated plus maze test. 
 
3.5. Metabolic measurements 
Experimental mice were singly housed for 1 week before training. Then, the mice were 
housed in training boxes for 3 days for acclimatization to learn the use of feeders and 
drinking bottles. On the first day of acclimatization, body composition was measured by 
magnetic resonance imaging (MRI) scan (EchoMRI). One day long control measurement 
was performed in metabolic boxes (TSE Phenomaster) in normal circumstances after 
training (baseline). Then, mice were exposed to 1 h restraint acute stress. In case of virus-
injected mice, control measurements were done after a saline injection, while the 
experimental mice were injected by clozapine-N-oxide (CNO). CNO was dissolved in 0,9 
% saline solution (1 mg/ml) and was injected i.p. (dose:1mg/kg body weight). Control 
virus injected mice were treated by saline or CNO. After inducing stress response, and 
CNO/saline injections, the metabolic measurement was continued for further 24 hours. 
Experimental design and timeline diagram is shown on figure 7.   
Chronically stressed mice were placed into metabolic cages and their metabolic 
changes were measured after the last stress of the CVS protocol for three days. Data of 
the first day were regarded as stress effect on metabolism and data of the third day were 
considered as recovery. Food- and O2 consumption, CO2 production and X-Y-Z 
locomotor activity data were automatically collected during the metabolic measurements. 
Energy expenditure (EE (kcal/h)) was calculated using a rearrangement of the abbreviated 
Weir equation as supplied by TSE Labmaster System: EE= (3.941 (VO2) + 1.106 




following formula: VCO2/VO2. The body composition was determined again at the end 
of metabolic measurements.  
 
Figure 7. Experimental overview of the CNO induced metabolic measurement. 
 
3.6. Behavior tests 
3.6.1. Sucrose consumption test 
Sucrose consumption test was performed before the CVS part of two hits protocol and 
one day after chronic stress. Mice had free choice for 24h between two bottles: one with 
1% sucrose solution and the other filled with tap water. The position of the two bottles 
was switched after 12h. Sucrose and tap water intakes were assessed by weighing bottles. 
The sucrose consumption was expressed as a percentage of total liquid intake. As we did 
not habituate the animals to sucrose, this test measures neophobia rather than sucrose 
preference [89]. 
3.6.2. Open field test 
In open field test, mice were placed in the center of a 40x40x30cm, white, non-
transparent plastic box and their exploration was video-recorded from above for 10 min 
and then analyzed by Noldus EthoVision XT 10 program. The open field was divided 
into 16 squares by a 4x4 grid in the software. The four inner squares of the grid were 
considered as central area.  
3.6.3.  Novel environment test 
The first five minutes of the mouse behavior in the open field arena was analyzed by 
Solomon Coder software. Four different behavior elements were differentiated in this 
analysis: walk, survey, rearing and grooming. The analysis was carried out by two 
individuals blinded to subject treatment group. Walking was noted when the mouse 




when all paws were on the floor and head directed upwards. Rearing was noted when two 
hind legs were on the floor and head directed upwards. 
3.6.4. Elevated plus maze 
The elevated plus maze (arm length-30 cm, arm width-7 cm, wall height-30 cm 
platform height-80 cm) apparatus was made of dark-grey painted Plexiglas. Open arms 
were surrounded by 0,3 mm high ledges. Mice were placed into the central area of the 
platform facing to one of the open arms and were allowed to explore the apparatus for 5 
min. Mice were considered to enter a compartment when all four legs crossed the lines 
separating the compartments. Videos were analyzed by Noldus Observer software. 
Percentage of time spent in closed arms was used as a measure anxiety-like behavior. 
 
3.7. Gut permeability test in vivo 
To assess gut permeability, four experimental groups were formed: control, vehicle 
treated; control, rifaximin treated; chronically stressed, vehicle treated and chronically 
stressed, rifaximin treated mice. The dose of rifaximin was 300 mg/kg, vehicle was 5% 
hypromellose) After overnight of fasting, all animals received FITC-labelled 4kDa 
Dextran (Sigma-Aldrich) via oral gavage (dose: 44 mg/kg; 100 mg/ml). 2 hours later, 
250-300 µl blood was collected from heart, centrifuged and serum was collected. Serum 
samples were diluted with an equal volume of PBS and FITC concentration was measured 
from 100 µl of diluted serum at excitation 485nm and emission 535nm wavelength using 
Cytation 5 Cell Imaging Multimode reader (Biotek Instruments). A standard curve was 
obtained by serial dilution of FITC-dextran solution in PBS (range: 0-16000 ng/ml). 
Equal volume of non-hemolytic serum from non- gavaged mice was added to the serial 
dilution before measurement.  
 
3.8. Hormone, endotoxin, glucose and triglyceride measurement 
from plasma 
Plasma corticosterone was measured from 10µl plasma by direct RIA as described 




To determine plasma endotoxin levels, commercially available limulus amebocyte 
lysate (LAL) assay was used in accordance of the manufacturer’s instructions (Pierce 
LAL Chromogenic Endotoxin Quantitation Kit, Thermo Scientific). 
Plasma glucose level was determined by Glucose Colorimetric Detection Kit from 
plasma according to the manufacturer’s protocol (Glucose Colorimetric Detection Kit, 
Invitrogen).  
Plasma triglyceride (TG) level was measured by multiparameter diagnostic device for 
triglycerides (MultiCare-in; Biochemical Systems International Srl). 
 
3.9. Gene expression analysis 
Frozen colon tissue samples were homogenized by Bertin Technology Minilys 
homogenizer in 300 µl TRI reagent. Then, total mRNA was isolated from the homogenate 
using a Total mRNA Mini Kit (Geneaid) according the manufacturer’s instruction. To 
eliminate genomic DNA contamination, DNase I (Fermentas) treatment was used. 
Sample quality control and the quantitative analysis were carried out by NanoDrop 
(Thermo Scientific). cDNA synthesis was performed with High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems). Real-Time PCR was carried out in ABI 
StepOnePlus instrument (Applied Biosystems) with Fast EvaGreen quantitative PCR 
master mix (Biotium) and gene-specific primers. Primers (Microsynth) were designed in 
our laboratory using Primer-BLAST software of the National Center for Biotechnology 
Information (NCBI). Forward and reverse primers used to quantify different mRNAs are 
listed in Table 2. Gene expression was analyzed by the 2-ΔΔCT method using the ABI 
StepOne Software v2.3 (Applied Biosystems). The amplicons were tested by melt curve 
analysis on ABI StepOnePlus instrument (Applied Biosystems). Relative changes in gene 
expression were normalized against GAPDH mRNA expression. Reference gene was 











Table 2. Forward and reverse primers for the selected genes 
Genes Forward primer Reverse primer 
GAPDH TGACGTGCCGC TGGAGAAA AGTGTAGCCCAAGATGCCCTTCAG 
TJP1 CGGCCGCTAAGAGCACAG TGGAGGTTTCCCCACTCTGA 
TJP2 GCAGAGACAACCCCCACTTT CTTGACCACGATGGCTGCTA 
TJP3 ACAGCATGCGGACCTACAAG AGCCCTCGTCATCAGAGG AT 
Occludin CCGGCCGCCAAGGTTC CATGCATCTCTCCGCCAT 
MUC2 GCTGACGAGTGGTTGGTGAATG GATGAGGTGGCAGACAGGAGAC 
Reg3b ACCCTCCGCACGCATTAGTT TTTGGCAGGCCAGTTCTGCAT 
Retnlb TCAGTCGTCAAGAGCCTAAGAC AGTCTGCCAGAAGACGTGAC 
 
3.10. Microbiome analysis 
Total DNA was extracted from 200 mg colon content using QIAamp DNA Stool Mini 
Kit (Qiagen) according to the manufacturer’s protocol. Total genomic DNA 
concentration and quality control was checked by using NanoDrop (Thermo Fisher). 
Targeting the bacterial 16S ribosomal RNA gene, dominant taxon of the gut microbiome 
were analyzed by real time quantitative PCR with Fast EvaGreen quantitative PCR master 
mix (Biotium) and taxon specific primers (Table 3.) on ABI StepOnePlus instrument 
(Applied Biosystems). In case of Proteobacteria, primer specificity for the phylum could 
not be confirmed, therefore, different subdivisions of the phylum were determined 
(Alpha-, Beta-, Epsilon- and Gamma-Proteobacteria). The position of the specific 
primers in 16S rRNA gene and primer references are found in Table 3. The primer 
specificity was tested by Melt Curve Analysis. DNA samples were diluted to the same 
concentration 5ng/µl. Quantification was done by using standard curves made from 
known concentrations of the respective amplicon for each set of primers. Gene expression 
was analyzed using ABI StepOne v2.3 program (Applied Biosystems). The results are 
expressed in copy number (CN) and it was calculated with the following formula: CN = 
A*6x1023/(L*660)*1x109 ng/g; where A is the amount of the amplicon in ng, L is the 





Table 3. Forward and reverse primers of the targeted microorganism, the PCR 



























































3.11. Bacterial load in mesenteric lymph node 
Mesenteric lymph nodes (MLN) were aseptically collected and stored at -70°C. Total 
DNA was isolated from MLN by Tissue Genomic DNA Mini Kit (Geneaid) according to 
the manufacturer. DNA concentration and quality control was checked by using 
NanoDrop (Thermo Scientific). Samples were diluted to the same DNA concentration. 
Then total DNA was amplified targeting bacterial 16S rRNA gene by using a universal 




3.12. Histological methods  
3.12.1. Perfusion and tissue processing 
24h after metabolic measurement, restraint stress was repeated on CRH-Ires-Cre x 
tdTomato transgenic mice. In rAAV8/hsyn-DIO-hM3D(Gq)-mCherry injected mice, a 
second treatment with CNO was performed. Two hours after the beginning of stress or 
CNO injection, (at the maximum of cFos expression) mice were anesthetized and 
perfused with ice cold fixative (4% paraformaldehyde in 0.1 M phosphate buffer pH 7.2) 
for histology. Chronically stressed mice, which were kept in metabolic cages, were 
perfused 72h after metabolic measurements. The fixed brain tissue was dissected, post-
fixed in the same fixative supplemented with 10% sucrose and incubated overnight in 
KPBS with sucrose. Then, coronal sections (20 μm) were cut on freezing microtome and 
stored in cryoprotectant at −20 °C until use.  
In case of rifaximin experiment, cleaned colon samples was placed immediately after 
decapitation into 10% buffered paraformaldehyde (pH=7.4) for 24 h. Fixed tissues were 
embedded in paraffin and sectioned 5 µm thick sections in two parallel series.  
3.12.2. Haematoxylin & eosin staining, imaging and quantification  
One series of the two parallel colon sections was deparaffinized and stained with 
haematoxylin & eosin (H&E) according to a standard protocol. Images of stained colon 
sections were captured under 20x magnification with Spot RT color digital camera on 
Nikon Eclipse 6000 microscope. Mucosa thickness was measured by using ImageJ 
software, in a blinded manner. From each mouse, five sections were randomly selected, 
from each section, 10 measurements were done and averaged.  
3.12.3. Immunostaining, imaging and quantification 
To check the place of virus injections and to verify the effect of acute stress, free-
floating coronal brain sections were washed three times in KPBS. To avoid nonspecific 
binding, sections were incubated in 2% normal donkey serum (Jackson ImmunoResearch 
Laboratories) in PBS/0,3% Triton X100 at room temperature for 1h. Then, sections were 
incubated in rabbit anti-c-Fos antibody made in rabbit primer (sc-52 Santa Cruz 
Biotechnology, Santa Cruz, CA, 1:10000) at 4°C for 72h. After 3 times washing, sections 
were incubated in anti-rabbit Alexa Fluor 488 secondary antibodies produced in donkey 




washed again in KPBS and were cover-slipped with DAPI Fluoromount-G 
(SouthernBiotech). Digital images of hypothalamic paraventricular nucleus (PVN) were 
captured using Nikon C2+ confocal microscope. 
F4/80 (murine macrophage marker) immunostaining was performed on colon samples 
by an immunohistochemical protocol for paraffin embedded sections. Slides were 
deparaffinized and rehydrated. Antigen retrieval pre-treatment was performed with 
proteinase K (Sigma; 10 mg/ml; diluted 1:25 in digestion puffer: 1M Tris and 0,5M 
EDTA). In this immunostaining, endogenous peroxidase was blocked by 0,3% H2O2. 
Next, slides were incubated in 2,5% normal rabbit serum then incubated in anti-mouse 
F4/80 antibody made in rat (BMA Biomedicals, T-2008; 1:50) overnight at 4°C in 
humidified boxes. After washing, slides were incubated in biotinylated secondary 
antibody (Vector Laboratories, 1:250) for 1 h. Then, immunoreactivity was visualized 
with Alexa FluorTM 488 Tyramide SuperBoostTM Kit, according to the manufacturer’s 
instructions (Invitrogen by Thermo Fisher Scientific). Slides were cover slipped with 
DAPI Fluoromount-G (SouthernBiotech) and scanned with Pannoramic MIDI II Slide 
Scanner. Images were analyzed with Caseviewer 2.3. software by two different 
investigators, who were blinded to treatment. For quantitative analysis of the area% 
occupied by F4/80 immunoreactivity, ten images from each mouse were randomly 
selected and re-opened in Image J software. All images were set at a common threshold 
level and F4/80 positive areas were selected. Background subtraction procedure was 
performed equally in each image. The entire immunoreactive area fraction was then 
automatically measured by the program, with the same threshold. Area % was measured 
separately for submucosa and lamina propria. 
 
3.13. Epidemiological data collection  
Antibiotic consumption data, collected between 1997-2009 by the ESAC project 
(European Surveillance of Antibiotic Consumption network) and data from the ECDC 
(European Centre for Disease Prevention and Control) database (2010-2017) were used. 
Within the penicillin group, consumption data of narrow spectrum penicillins (J01CE) 
plus penicillinase resistant penicillins (J01CF) and the extended spectrum penicillins 
(J01CA) plus β lactamase inhibitor combination penicillins (J01CR) were separately 




were obtained from [100]. Correlation was calculated between antimicrobial consumption 
data and changes in PD prevalence. 
 
3.14. Statistics 
All data are shown as means ± SEM. Unpaired or paired two tailed Student’s t-test 
were used when significant differences was determined between two groups. Statistical 
analysis was performed by two-way ANOVA (GraphPad Prism 7) followed by Sidak’s 
multiple comparison test when the mean differences was calculated between groups that 
have been split on two independent factors. In case of sugar preference, data was analyzed 
by repeated-measures ANOVA followed by Sidak’s post hoc test. Time was the repeated 
measure in paired two tailed Student’s t-test and repeated-measures ANOVA. Correlation 
analysis was performed in our medical hypothesis between antimicrobial consumption 
and changes in PD prevalence. In all cases, differences were considered statistically 
























4.1. Basal metabolic and locomotor activity 
Control, basal metabolic measurements were done on intact C57BL/6J mice for 72h. 
As seen on Fig. 8, locomotor activity and all metabolic parameters show circadian 
rhythmicity. Their locomotor activity, food intake, energy expenditure (EE) and 
respiratory exchange ratio (RER) are higher in the dark phase compared to the light phase 
(locomotor activity: F(1,3) = 15.47; p = 0.0293; food intake: F(1.3) = 17,68; p = 0.0245; 
EE: F(1,3) = 39,94; p = 0.008; RER: F(1,3) = 24.4; p = 0.0159). Two distinct peaks occur 
in all parameters during the active phase: the first at the beginning of dark phase and the 





Figure 8. Basal metabolic measurement. 
Baseline recordings of locomotor activity, food intake, energy expenditure (EE), 
respiratory exchange ratio (RER) and average of these activities in the light and dark 
phases. Data were analyzed by repeated two-way ANOVA (n =4). Time being the 





4.2. Acute restraint stress 
Neuronal activity in the hypothalamus of CRH IRES Cre/TdTomato mice, as assessed 
by c-Fos immunostaining revealed selective activation of CRH neurons in response to 1h 
restraint stress. 60,5% of the CRH neurons were c-Fos positive in PVN of stressed mice. 
By contrast, CRH (Tomato) and c-Fos colocalization was not observed in the PVN of 
control, non-stressed mice (Fig. 9A). ACTH and corticosterone plasma levels were 
significantly increased in stressed mice compared to the controls [ACTH: t = 9.052; DF 
= 4; p = 0.0028; corticosterone: t = 4.461; DF = 4; p =0.0112] (Fig. 9B-C).  
 
Figure 9. Effectiveness of acute stress. 
Representative images of the hypothalamic paraventricular nucleus (PVN) from control 
and restrained mice. Red- tdTomato fluorescent protein expression in CRH neurons of 
CRH-IRES-Cre mice Green- c-Fos immunolabelled cell nuclei. Yellow- Stress-activated 
CRH neurons. 3V- third ventricle. Scale bar is 100µm (A) [not published] Plasma ACTH 
level (B) and plasma corticosterone level (C) in control vs. acutely restrained male mice. 
[101]. Data were analysed by unpaired t-test (n =3). Mean ± SEM values, *p<0.05, 





4.3. Effects of acute psychological stress on locomotor behaviour 
and metabolic variables  
4.3.1. Locomotor activity 
Stressed mice displayed increased locomotor activity in the first hours after acute stress 
[measurement points during the first hour: 1. point: t = 0.3764; DF = 168; p = >0.9999; 
2. point: t = 1.025; DF = 168; p = 0.9999; 3. point: t = 1.582; DF = 168; p = 0.9535; 4. 
point: t = 3.464; DF = 168; p = 0.0168; 5. point: t =3.656; DF = 168; p = 0.0085], it 
reminded elevated in the following three hours (Fig. 10B), however, average of the first 
four hours were not significantly changed [F(1,7) = 2.446; p = 0.1618] (Fig. 10C). The 
average locomotor activity was not changed when in the entire light phase was analyzed 
[F(1,7) = 1.427; p = 0.2712] (Fig. 10D). Nevertheless, locomotor activity of stressed 
animals was significantly decreased in dark phase compared to the basal measurements 







Figure 10. Acute stress effect on locomotor activity. 
Daily timeline of locomotor activity after acute restraint stress compared to basal 
measurements (A). The first four (4) hour timeline of locomotor activity after acute stress 
compared to the basal measurements (B). Average locomotor activity in the first four 
hour (C), in the light phase (D) and in the dark phase (E) after acute stress. Data were 
analyzed by repeated measures two-way ANOVA. In case of the first four hours ANOVA 
was followed by Sidak’s multiple comparison test (n =8). Time and treatment being the 







4.3.2. Cumulative food intake 
Stressed mice consumed more food in the first four hours after acute stress. After the 
third hour, significant difference was noticed between basal measurement and the 
measurements after acute stress [measurement points during the fourth hour: 1. point: t = 
3.16; DF = 168; p = 0.0457; 2. point: t = 3.917; DF = 168; p = 0.0033; 3. point: t = 4.34; 
DF = 168; p = 0.0006; 4. point: t = 3.316; DF = 168; p = 0.0276; 5. point: t = 3.539; DF 
= 168; p = 0.0129; 6. point: t = 3.872; DF = 168; p = 0.0038] (Fig. 11B). However, this 
difference was equalized later and the cumulative food intake was not changed neither in 
the entire light phase [t = 0.9107; DF = 7; p = 0.3927] (Fig. 11D) nor in the entire dark 











Figure 11. Effect of acute stress on food intake. 
Daily timeline of cumulative food intake after acute restraint stress compared to the basal 
measurements (A). The first four hour timeline of cumulative food intake after acute stress 
compared to the basal measurements (B). Average cumulative food intake in the first four 
hour (C), in the light phase (D) and in the dark phase (E) after acute stress. Difference 
of cumulative food intake was tested by paired t-test. Time being the repeated measures. 
During the first four hours, significance of the continuous changes was analyzed by 
repeated measures two-way ANOVA followed by Sidak’s multiple comparison test (n=8). 
Time and treatment being the repeated measures. Mean ± SEM values, *p<0.05, 







4.3.3. Energy expenditure (EE) 
Energy expenditure (EE) was higher during the first four hours after acute stress 
[F(1,7) = 15.25; p = 0.0059] (Fig. 12B-C) and it was also significantly elevated in the 
entire light phase compared to the basal measurement [F(1,7) = 15; p = 0.0061] (Fig. 
12D). However, there was no difference in the dark phase [F(1,7) = 0.000609; p = 0.981] 
(Fig. 12E). 
 
Figure 12. Effect of acute stress on energy expenditure. 
Daily timeline of energy expenditure after acute restraint stress compared to the basal 
measurements (A). The first four hour timeline of energy expenditure after acute stress 
compared to the basal measurements (B). Average energy expenditure in the first four 
hour (C), in the light phase (D) and in the dark phase (E) after acute stress. Data were 
analyzed by repeated measures two-way ANOVA (n =8). Time and treatment being the 




4.3.4. Respiratory exchange ratio (RER) 
RER is the ratio of carbon dioxide production (VCo2) and oxygen (VO2) used. The value 
indicates the predominant fuel source. The value usually changes between 0.7 and 1. RER 
of 1 indicates that carbohydrates was metabolized as the predominant fuel and RER of 
0.7 indicates fat utilization. As seen on Figure 9, there were not significant differences in 
the utilization of energy sources in the first four hours (Fig. 13B-C) after acute stress 
neither in the light phase (Fig. 13D) nor in the dark phase (Fig. 13E).  
 
Figure 13. Effect acute stress on respiratory exchange ratio (RER). 
Daily timeline of RER after acute restraint stress compared to the basal measurements 
(A). The first four hour timeline of RER after acute stress compared to the basal 
measurements (B). Average RER in the first four hour (C), in the light phase (D) and in 
the dark phase (E) after acute stress. Data were analyzed by repeated measures two-way 
ANOVA. In case of the first four hours ANOVA was followed by Sidak’s multiple 
comparison test (n =8). Time and treatment being the repeated measures. Mean ± SEM 




4.3.5. Body composition 
Body composition was measured before the beginning of 1h restraint stress and it was 
measured again 24h later by MRI. As seen on Figure 8., body weight and fat mass were 
decreased 24 hours later of acute stress [body weight: t = 2.437; DF = 7; p = 0.045; fat 
mass: t = 4.467 DF = 7; p = 0.0029] (Fig 14A-B). In lean mass, there was no effect of 
acute stress [t = 1.887; DF = 7; p = 0.1011] (Fig. 14C).  
 
Figure 14. Effect of acute stress on body composition.  
Body weight (A), fat mass (B) and lean mass (C) before and 24hours after acute restraint 
stress. Fat and lean mass represented as the percentage of body weight. Data were 
analyzed by paired t-test (n =8). Mean ± SEM values, *p<0.05, **p<0.01 vs. control 
group [not published]. 
 
4.4. Chemogenetic activation of CRHPVN neurons 
To reveal the contribution of stress-related CRH expressing neurons in challenge-
induced locomotor and metabolic changes we chemogenetically manipulated these 
neurons in the paraventricular nucleus. To confirm that paraventricular CRH neurons 
(CRHPVN) become activated after triggering Gq-DREADD receptors, CRH-IRES-Cre 
mice, -previously injected by Cre-dependent pAAV-hSyn-DIO-hM3D(Gq)-mCherry 
vector into the hypothalamic PVN region- received CNO injection (i.p.). Control animals 
were injected with pAAV-hSyn-DIO-mCherry vector and also challenged with CNO. In 
both cases, c-Fos expression was used an indirect marker of neuronal activity. As showed 
on Fig. 15., c-Fos induction was seen only in DREADD expressing mice. It has been 
noted that c-Fos expression after activation of CRHPVN neurons goes beyond the nucleus 
and seen in non CRH neurons the peri-paraventricular region, possibly due to secondary 






Figure 15. Activation of CRH neurons in PVN by DREADD. 
Representative images of the paraventricular hypothalamic area of control and DREADD 
virus injected mice. Red- mCherry fluorescent protein in CRH neurons; Green- c-Fos 
immunoreactive neurons. 3V-third ventricle. Scale bar is 100µm [not published]. 
 
4.5. Effect of CRHPVN activation on locomotor behavior and 
metabolism 
4.5.1. Locomotor activity 
Locomotor activity did not change significantly after activation of CRHPVN neurons 
within the first four hours after i.p. CNO treatment [F(1,6) = 1.422; p = 0.2781] (Fig. 
16B-C), although there was a tendency for increased locomotion, when compared to 
saline injected mice.  Similarly, there was no change in the average of locomotion neither 
in the light [F(1,6) = 0.2377; p = 0.6432] (Fig. 16D) nor in the dark phase [F(1,6) = 0.7; 





Figure 16. Effect of activation of CRHPVN neurons on locomotor behavior 
Locomotor activity of CRH-IRES-Cre mice injected by pAAV-hSyn-DIO-hM3D(Gq)-
mCherry vector into the PVN after CNO/saline treatment (A). The first four hour timeline 
of locomotor activity after CNO or saline (B). Average locomotor activity in the first four 
hour (C), in the light phase (D) and in the dark phase (E) after i.p. injections. Data were 
analyzed by repeated measures two-way ANOVA (n =7). Time and treatment being the 
repeated measures. Mean ± SEM values [not published]. 
 
4.5.2. Cumulative food intake 
The average of cumulative food intake was significantly higher in the first four hours 
after CNO injection [t = 3.53; DF = 6; p = 0.0124] (Fig. 17B-C). However, there was no 
difference in cumulative food intake in the entire light phase [t = 1.761; DF = 6; p = 
0.1287] (Fig. 17A and D), however, it was significantly decreased in the dark phase [t = 





Figure 17. Effect of chemogenetic activation of CRHPVN neurons on cumulative food 
intake. 
Daily timeline of cumulative food intake after CNO treatment compared to the 
measurements after saline injection (A). The first four hour timeline of cumulative food 
intake after CNO/saline injections in DREADD expressing mice (B). Average cumulative 
food intake in the first four hour (C), in the light phase (D) and in the dark phase (E) after 
activation of CRHPVN neurons. Data were analysed by paired t-test (n =7). Time being 
the repeated measures. Mean ± SEM values, *p<0.05 vs. control group [not published]. 
 
4.5.3. Energy expenditure (EE) 
After CNO injection, average of energy expenditure was significantly higher in the 
first four hour [F(1,6) = 15.61; p = 0.0075] (Fig. 18B-C). After the fourth hour, there was 
no difference in EE between saline and CNO treatment and the average of energy 
expenditure did not changed neither in the light (Fig. 18D) nor in the dark phase [light: 





Figure 18. Effect of chemogenetic activation of CRHPVN neurons on the energy 
expenditure. 
Daily timeline of energy expenditure after CNO treatment compared to the measurements 
after saline injection (A) in CRH-IRES-Cre mice injected with virus vectors encoding 
stimulatory DREADDs. The first four hour timeline of energy expenditure after activating 
CRHPVN neurons by CNO (B). Average energy expenditure in the first four hour (C), in 
the light phase (D) and in the dark phase (E). Data were analysed by repeated measures 
two-way ANOVA (n =7). Time and treatment being the repeated measures. Mean ± SEM 
values, **p<0.01 vs. control group [not published]. 
 
4.5.4. Respiratory exchange ratio (RER) 
There was no difference in the respiratory exchange ratio during 23 hours of metabolic 
measurements after CNO injection compared to RER values after saline injection [first 4 
hour: F(1,6) = 0.03247; p = 0.8629; light: F(1,6) = 0.1221; p = 0.7387; dark: F(1,6) = 





Figure 19. Effect of chemogenetic activation of CRHPVN neurons on respiratory 
exchange ratio. 
Daily timeline of respiratory exchange ratio after CNO treatment compared to the 
measurements after saline injection (A). The first four hour timeline of RER after 
CNO/saline injections in DREADD expressing mice (B). Average respiratory exchange 
ratio in the first four hour (C), in the light phase (D) and in the dark phase (E). Data were 
analyzed by repeated measures two-way ANOVA (n =7). Time and treatment being the 
repeated measures. Mean ± SEM values [not published]. 
 
4.5.5. Body composition 
Body composition changes of DREADD expressing mice, was measured by MRI on 
the first day of acclimatization and at the end of metabolic measurements. As shown on 
Fig. 20, body weight and fat mass were significantly reduced [body weight: t = 2.541; DF 
= 6; p = 0.0440; fat mass: t = 2.954; DF = 5; p = 0.0317] and lean mass did not change [t 





Figure 20. DREADD induced stress effect on body composition.  
Basal body weight at the first day of acclimatization (blue) and body weight at the end of 
measurements (red) (A). Fat mass at the first day of acclimatization (blue) and fat mass 
at the end of measurements (red) (B). Basal lean mass at the first day of acclimatization 
(blue) and lean mass at the end of measurements (red) (C). Fat and lean mass represented 
in the percentage of body weight. Data were analysed by paired t-test (n =8). Time being 
the repeated measures. Mean ± SEM values, *p<0.05 vs. control group [not published]. 
 
4.6. Control experiments 
To examine whether CNO injection or virus injection are able to influence the 
metabolic system, control virus injected mice (DREADD gene was not included in 
plasmid (see chapter 4.2.) were kept in metabolic cages for 24h and their metabolic 
changes were measured after CNO injection. These results were compared to intact 
control mice and to DREADD injected mice after saline treatment. Locomotor activity of 
both virus injected mice (control and DREADD containing virus) was decreased in the 
dark phase compared to the intact control mice, however, this reduced locomotor activity 
was significant only after CNO injection [DREADD virus + saline vs. intact control: q = 
2.735; DF = 65; p = 0.1373; control virus + CNO vs. intact control: q = 5.811; DF = 65; 
p = 0.0003] (Fig 21A). The average food intake, EE and RER did not changed neither in 
light nor in dark state after CNO treatment [Food intake - DREADD virus + saline vs. 
intact control: q = 0.9666; DF = 65; p = 0.7739; control virus + CNO vs. intact control: q 
= 0.7158; DF = 65; p = 0.8686; EE - DREADD virus + saline vs. intact control: q = 2.261; 
DF = 65; p = 0.2534; control virus + CNO vs. intact control: q = 0.6945; DF = 65; p = 
0.8758; RER - DREADD virus + saline vs. intact control: q = 0.6873; DF = 65; p = 
0.8782; control virus + CNO vs. intact control: q = 0.04946; DF = 65; p = 0.9993] (Fig 




after i.p. injection compared to intact control mice [DREADD virus + saline vs. intact 
control: q = 5.266; DF = 9; p = 0.0119; control virus + CNO vs. intact control: q = 4.064; 
DF = 9; p = 0.044] (Fig. 21C). 
 
Figure 21. Effectiveness of virus injection and CNO injection on metabolic system. 
Daily timeline of locomotor activity (A), food intake (B), energy expenditure (C) and 
respiratory exchange ratio (D). Blue – intact control (n=8), white – control virus + CNO 
i.p. injection (n=4) and black – DREADD virus + saline i.p. injection (n=7). Data were 
analysed by one-way ANOVA followed by Tukey’s multiple comparisons test. Mean ± 
SEM values (not published). 
 
4.7. Effects of chronic stress   
Mice exposed to chronic stress did not gain significant body weight by the end of stress 
protocol, when compared to non-stress controls as shown on Fig.18. [control – compared 
to initial bodyweight: t = 4.359; DF = 16; p = 0.001; CVS - compared to initial body 
weight: t = 1.588; DF = 16; p = 0.2464] (Fig. 22A). To check the behavioral effect of the 
CVS, mice were exposed to open field one day after the end of CVS procedure. 
Chronically stressed mice spent significantly less time in centrum (t = 2.332; DF = 8; p = 




DF = 8; p = 0.0065) (Fig. 22E) compared to non-stressed controls. These mice were then 
sacrificed and different stress markers measured. CVS resulted in adrenal enlargement [t 
= 2.492; DF = 8; p = 0.0374] (Fig. 22B) and increased plasma corticosterone level [t = 
2.532; DF = 8; p = 0.0351] (Fig. 22C).  
 
Figure 22. Effects of chronic stress on body weight, adrenals, plasma hormone level 
and behaviour. 
Body weights of control (blue) and chronically stressed mice before and after CVS 
protocol (A). Normalized adrenal gland weight (B). Plasma corticosterone level (C). 
Center preference (D) and the first latency to corner (E) during open field test. Data were 
analyzed by unpaired t-test (n=5/group). Mean ± SEM values, *p<0.05, **p<0.01, 
***p<0.001 vs. control group. In case of body weight gain, repeated two-way ANOVA 
followed by Sidak’s multiple comparison test were done (n =9). Time being the repeated 






4.8. Effect of chronic variable stress on metabolism 
After the CVS procedure, metabolic changes of the experimental mice were measured 
for 72 h. The first 24h (right after the CVS protocol) of the measurements were considered 
as stress effect and the last 24h was regarded as recovery of CVS exposed mice. 
 
4.8.1. Locomotor activity 
The average of locomotor activity chronically stressed mice was significantly higher 
in the light phase [q = 3.91; DF = 31; p = 0.0009], In the dark phase, locomotor activity 
was not changed significantly during the three days of measurements after CVS compared 
to the control mice [control vs. stress effect q = 2.144 DF = 33; p = 0.0716; control vs. 








Figure 23. Chronic stress effect on locomotor activity. 
Daily timeline of locomotor activity in control mice (blue) and mice exposed to chronic 
variable stress, CVS (red). (A). Average locomotor activity after chronic stress (red) 
during recovery (green) and in controls (blue) in the light and dark periods (B). Data 
were analysed by one-way ANOVA followed by Dunnett’s multiple comparison test. 
Significance was calculated by repeated two-way ANOVA between stress effect and 
recovery (n =4). Time being the repeated measures. Mean ± SEM values, ***p<0.001 vs. 








4.8.2. Cumulative food intake 
Food consumption of the stressed mice was higher after CVS procedure but it was 
elevated significantly only during the active phase [light: q = 1.175; DF = 9; p = 0.4274; 
dark: q = 2.818; DF = 9; p = 0.0361]. The cumulative food intake reminds elevated during 
recovery compared to the control mice, however, it was not significant [light: q = 0.184; 
DF = 9; p = 0.9756; dark: q = 1.48; DF = 9; p = 0.2853] (Fig. 24A-B). 
 
Figure 24. Chronic stress effect on cumulative food intake. 
Daily timeline of cumulative food intake after chronic stress (red), during recovery 
(green) and control mice (blue) (A). Average cumulative food intake after chronic stress 
(red), during recovery (green) and in control mice (blue) in the light and dark phase (B). 
Data were analyzed by one-way ANOVA followed by Dunnett’s multiple comparison test. 
Significance was calculated by paired t-test between stress effect and recovery (n =4). 





4.8.3. Energy expenditure 
Energy expenditure of chronically stressed mice was continuously higher during the 
three days of metabolic measurements compared to control mice [control vs. stress effect 
- light: q = 20.6; DF = 33; p = <0.0001; dark: q = 10.3; DF = 33; p = <0.0001; control vs. 
recovery - light: q = 13.45; DF = 33; p = <0.0001; dark: q = 8.009; DF = 33; p = <0.0001]. 
However, statistical analyses revealed that during recovery, the average energy 
expenditure was decreased significantly in the active phase compared to the energy 
expenditure of stress effect [F(11, 36) = 2.325; p = 0.028] (Fig. 25A-B). 
 
Figure 25. Effect of chronic stress on energy expenditure. 
Daily timeline of energy expenditure after chronic stress (red), during recovery (green) 
and control mice (blue) (A). Average energy expenditure after chronic stress (red), during 
recovery (green) and in control mice (blue) in the light and dark phase (B). Data were 
analyzed by one-way ANOVA followed by Dunnett’s multiple comparison test. 
Significance was calculated by repeated two-way ANOVA between stress effect and 
recovery (n =4). Time being the repeated measures. Mean ± SEM values, ****p<0.0001 




4.8.4. Respiratory exchange ratio (RER) 
During metabolic measurements, respiratory exchange ratio was continuously higher 
in the stressed mice after CVS procedure [light: q = 2.872; DF = 33; p = 0.0134; dark: q 
= 3.19; DF = 33; p = 0.006], however, the average RER of the stressed mice was dropped 
after two days to the control level but only under the light phase [light: q = 0.4596; DF = 
33; p = 0.859; dark: q = 3.899; DF = 33; p = 0.0009] (Fig. 26A-B).  
 
Figure 26. Effect of chronic stress on respiratory exchange ratio (RER). 
Daily timeline of respiratory exchange ratio after chronic stress (red), during recovery 
(green) and in control mice (blue) (A). Average respiratory exchange ratio after chronic 
stress (red), during recovery (green) and control mice (blue) in the light and dark state 
(B). Data were analysed by one-way ANOVA followed by Dunnett’s multiple comparison 
test. Significance was calculated by repeated two-way ANOVA between stress effect and 
recovery (n =4). Time being the repeated measures. Mean ± SEM values, *p<0.05, 





4.8.5. Body composition 
Body composition was determined at the beginning (end of CVS) and the end of 
metabolic measurements. As shown on Figure 27., there was no difference in body weight 
between stressed and control mice at the beginning of measurements. However, fat mass 
was significantly lower and lean mass was higher in chronically stressed animals 
compared to the controls. During recovery, in chronically stressed mice, fat and lean mass 
were restored to the control level and body weight significantly increased. 
 
Figure 27. Chronic stress effect on body composition.  
Body weight (A). Fat mass as % of body weight (B). Lean mass as % of body weight (C). 
Blue is the average of control mice, red is the average of stressed mice at the beginning 
and green is the average of CVS exposed mice at the end of measurement. Fat and lean 
mass represented in the percentage of body weight. Data were analysed by one-way 
ANOVA (n =4) and paired t-test was used to calculate significant differences between 
stress effect and recovery. Mean ± SEM values, *p<0.05, ***p<0.001 vs. control group, 











4.9. Effect of chronic stress on gut microbiome and its restoration 
after rifaximin treatment  
Next, we investigated the effect of chronic stress on gut microbiome. As shown on 
Fig. 28A exposure to “two hits” chronic stress paradigm resulted in significant reduction 
of DNA in the colon content indicating reduction of total colonic bacteria. Colon 
microbiome diversity was analyzed at phylum level and the results showed an increased 
abundance in the phylum of Bacteriodetes [F(1,17) = 5.844; p = 0.0272] and 
Proteobacteria [t = 2.665; DF = 17; p = 0.0324 compared to control]. Changes in 
Firmicutes, Actinobacteria, Verrucomicrobia and Cyanobacteria were not significant 
(Fig. 28B-C). Amount of Clostridium sp. was determined at genus level. Chronic stress 
resulted in increased abundance of Clostridium in response to stress (Fig. 28D) [t = 2.707; 
DF = 17; p = 0.0297 compared to control].  
Rifaximin is a non-absorbable gut-acting antibiotic, which selectively eliminates 
pathogenic bacteria from the gastrointestinal tract and relieves diarrhea associated with 
Clostridium difficile infections.  
Next, we have been interested in, if rifaximin treatment is able to restore stress-induced 
changes in gut microbiome. Antibiotic treatment reduced total DNA concentration in the 
colon content in non-stressed control animals while restored the abundance of 
Proteobacteria and decreased Clostridium sp (t = 3.233; DF = 17; p = 0.0098 compared 





Figure 28. Differences in the microbiome composition after chronic stress and 
rifaximin treatment. 
Total DNA concentration of colon content (A), copy numbers of bacterial phyla in the 
colon content (B, C). Copy number of Clostridium sp. in different experimental groups 
(D). Data were analyzed by two-way ANOVA, followed by Sidak’s multiple comparison 
test (n = 5–7 per group). Mean ± SEM values, *p < 0.05 vs. control group, #p < 0.05, ##p 
< 0.01, vs. MS + CVS-vehicle [102]. 
 
4.10. Effect of rifaximin treatment on chronic stress-induced 
changes in organ weights, hormones and metabolic markers  
Next, effects of rifaximin treatment was examined on different stress markers after 
MS+CVS procedure. During chronic variable stress, weight gain between experimental 
groups was not significantly different [F(1,18) = 0.2027; p = 0.8884)] (Fig. 29A). 
Normalized adrenal weight was higher in all MS + CVS exposed mice than in controls 
[F(1, 19)=4.512; p=0.047] (Fig. 29B). Two-way ANOVA did not reveal drug (rifaximin) 
effect. Thymus weights were not different among the groups [F(1, 19) = 1.759; p = 
0.2005]. During CVS procedure, basal (morning), pre-stress corticosterone levels were 




Two-way ANOVA indicated no drug effect [F(1, 18) = 0.1965; p = 0.6629] (Fig. 29C). 
Analysis of plasma corticosterone concentrations after acute EPM exposure revealed no 
significant differences among the treatment groups [F(1, 19) = 0.226; p = 0.6399] (Fig. 
23D). Plasma glucose levels following acute stress were elevated in chronically stressed 
mice compared to controls [F(1, 13) = 22.44; p = 0.0004] (Fig. 29E). In addition, post hoc 
test revealed elevated plasma TG level in stressed mice [t = 2.627; DF = 18; p = 0.0339 
compared to vehicle control], while there was no difference between the two, antibiotic 
treated groups (Fig. 29F). 
 
 
Figure 29. Effect of chronic stress and rifaximin treatment on different stress 
markers. 
Body weight gain during CVS (A). Normalized adrenal gland and thymus weights (B). 
Basal corticosterone level during CVS (C). Effect of single acute stress (EPM exposure) 
on corticosterone level after chronic stress (D), plasma glucose level (E), plasma 
triglyceride level (F). Data were analyzed by two-way ANOVA, followed by Sidak’s 
multiple comparison test (n = 5–7 per group). Mean ± SEM values, *p < 0.05 vs. control 





4.11. Effect of rifaximin on chronic stress-induced changes on 
behavior 
4.11.1. Ethogram 
To examine the effects of chronic stress and rifaximin on mouse behavior, we observed 
and quantified four distinct elements: walking, surveying, rearing and grooming during 5 
min in novel environment (Fig. 30A). Compared to no-stress controls, all mice which 
have been exposed previously to MS + CVS displayed exaggerated locomotor-related 
behavior. The frequencies of all four selected behavioral elements were increased 
significantly in stressed mice [survey: F(1, 41) = 66.76; p < 0.0001; walk: F(1, 41) = 
58.67; p < 0.0001; rear: F(1, 41) =49.28; p < 0.0001; groom: F(1, 41)=33.35; p < 0.0001] 
(Fig. 30B). Similarly, total duration of walking, rearing and grooming were increased 
significantly in stressed mice, however surveying decreased [surveying: F(1, 41) = 104.1; 
p < 0.0001; walking: F(1, 41) = 39.18; p < 0.0001; rearing: F(1, 41) = 37.69; p < 0.0001; 
grooming: F(1, 41) = 17.38; p < 0.0002] (Fig. 30C). Rifaximin treatment had no effect on 






Figure 30. Behavioral activity of control and chronically stressed mice with or without 
rifaximin treatment in a novel environment (open field arena) 
Each row represents one mouse (A). Frequency (B) and duration (C) of selected 
behavioral elements. Data were analyzed by two-way ANOVA (n = 9–14 per group). 












4.11.2. Open field, EPM, sucrose consumption test 
Increased locomotion was detected during the open field test in MS + CVS mice. 
Velocity [F(1, 41) = 24.24; p < 0.0001] and distance moved [F(1, 41)=24.29; p < 0.0001] 
was higher in chronically stressed mice (Fig. 31A–B). In addition, stressed mice spent 
less time in the center [F(1, 41) = 10.38; p = 0.0025] and their first latency to border was 
shorter than those of controls [F(1, 41) = 12.65; p < 0.0010] (Fig. 31C–D). To reveal 
anxiety-like behavior after MS + CVS, elevated plus maze test was performed. As shown 
in Fig. 31F preference for the open arms of stressed mice was significantly lower 
compared to control animals [F (1, 28) = 13.95; p = 0.0009]. Neophobia was assessed by 
sucrose consumption tests before and after the chronic stress procedure (Fig. 31G). MS + 
CVS resulted in a significant decrease of sucrose consumption (novelty) in stressed mice 
[t = 4.148; DF = 19; p = 0.0022] and the same reduced sucrose consumption was seen in 
CVS + antibiotic treated mice [t = 3.251; DF = 19; p = 0.0167], however, there was no 
difference in control groups. In each behavior tests (novel environment, open field, 















Figure 31. Anxiety-like behavior and neophobia after MS + CVS.  
Open field results: Velocity during open field test (A), distance moved (B) center 
preference (C) first latency in border (D) and exploration maps of the experimental mice 
(E). Open arm preference in elevated plus maze test (F). Data were analyzed by two-way 
ANOVA (n = 9–14 per group). Mean ± SEM values, **p < 0.01, ****p < 0.0001 vs. 
control group. Sugar consumption of experimental mice before and after CVS procedure 
(G). Data were analyzed by repeated measures two-way ANOVA followed by Sidak’s 
multiple comparison test (n = 5–7 per group). Mean ± SEM values, *p < 0.05, **p < 0.01 





4.12. Effect of MS+CVS and rifaximin treatment on the gut and 
gut-related immunity  
4.12.1. Colon mucosa, tight junction protein expression and gut 
permeability  
MS + CVS significantly reduced the thickness of colonic mucosa compared to control 
[t=3,082; DF=19; p=0.0122]. Mucosa thickness was not different in rifaximin-treated 
groups (Fig. 32A-B). Colonic mRNA expression (Fig. 32C) of tight junction proteins, 
occludin [F(1, 19) = 11.27; p = 0.0033] and tight junction proteins TJP1 [F(1, 19) = 6.26; 
p = 0.0216] and TJP2 [F(1, 19) = 6.613; p = 0.0187] but not TJP3 was increased in both 
rifaximin treated groups, but remained unchanged in response to stress. In case of MUC2 
mRNA there was no significant difference between the groups [F(1, 19) = 4.012; p = 
0.597]. Expression of Reg3b, a C-type lectin with antimicrobial activity, was significantly 
elevated in chronically stressed mice. Rifaximin treatment restored Reg3b mRNA level 
to that of the controls [t = 3.811; DF = 19; p = 0.0024 compared to control, t = 4.398; DF 
= 19; p = 0.0006 compared to vehicle, interaction: F(1, 19) = 10.21; p = 0.0048].  
Next, we tested gut permeability in vivo, using FITC-labelled 4 kDa dextran. Increased 
gut permeability has been revealed in chronically stressed mice, while rifaximin treatment 
restored the normal, non-stressed values [t = 2.72; DF = 18; p = 0.0301 compared to 
control, t = 3.449; DF = 18; p = 0.0066 compared to vehicle, interaction: F(1, 18) = 6.109; 








Figure 32. Effects of stress and rifaximin on colon mucosa.  
 Representative images of hematoxylin-eosin stained colon sections (A) (scale bar: 20 
μm) and bar graphs showing mean values ± SEM of mucosa thickness (B), mRNA levels 
of different permeability markers and antimicrobial defence-related genes from colon 
tissue (C), changes in gut permeability as measured by serum concentration of orally 
administered FITC-dextran (mean values ± SEM) (D). Data were analyzed by two-way 
ANOVA, followed by Sidak’s multiple comparison test (n = 5–7 per group). Mean ± SEM 
values, *p < 0.05, **p < 0.01, vs. non-stressed control group, #p < 0.05, ##p < 0.01, ###p 















4.12.2. Gut permeability, macrophage infiltration, local- and systemic 
bacterial load 
Next, we checked whether increased gut permeability results in local piling of 
macrophages in the gut mucosa. In control, vehicle-treated mice immunoreactivity 
corresponding to macrophage marker F4/80 was primarily confined to the submucosa. 
Essentially the same distribution was revealed in non-stressed, rifaximin-treated mice 
(Fig. 33A). However, in MS-CVS mice, an increase of F4/80 positive profiles and 
macrophage infiltration to the lamina propria was detected. Rifaximin treatment of MS-
CVS animals restored the distribution of F4/80 positive macrophages to that seen in 
control animals (Fig. 33A). Quantitative histological analysis of F4/80 positive (+) areas 
revealed significant rifaximin effect in the submucosa [F(1, 19) = 6.316; p = 0.0211]. In 
the lamina propria of MS-CVS animals, the area covered by F4/80+ profiles were 
significantly increased in stressed mice, which was reduced to that of the controls in 
response to rifaximin treatment [t = 14.69; DF = 19; p < 0.0001 compared to control, t = 
14.78; DF = 19; p < 0.0001 compared to vehicle, interaction: F(1, 19) = 105.4; p < 
0.0001], (Fig. 33B). Gut lymphatics are drained in mesenteric lymph nodes, which gate 
intestinal bacteria and pathogen-associated molecular patterns, PAMPs. To assess 
bacterial translocation in chronically stressed mice, we PCR amplified bacterial DNA 
from mesenteric lymph nodes using universal 16S ribosomal primers. Compared to non-
stressed controls, chronic stress resulted in 50% elevation of bacterial load in the MLN [t 
= 2.781; DF = 18; p =0.0245]. Rifaximin administration interfered with stress-induced 
increase of bacterial load (Fig. 33C). To reveal if chronic stress induces systemic 
endotoxemia, plasma LPS levels were measured. Higher LPS level was detected in 
plasma of stressed mice than in the controls [t = 2.61; DF = 18; p = 0.0351] but the 





Figure 33. Macrophage infiltration to lamina propria, local- and systemic bacterial 
load.  
Representative images of F4/80 immunostained colon sections showing distinct 
macrophage distribution (green-F4/80) in stressed and rifaximin-treated animals (on 
blue-DAPI background staining). (Scale bar: 100 μm) (A). Quantitative analysis of F4/80 
immunostaining in the submucosa and lamina propria (B). Bacterial load in the 
mesenteric lymph node expressed as % of control-vehicle group (C). Plasma LPS 
concentration in control, MS + CVS groups, with or without rifaximin treatment (D). 
Data were analyzed by two-way ANOVA, followed by Sidak’s multiple comparison test 
(n = 5–7 per group). Mean ± SEM values, *p < 0.05, **p < 0.01, vs. control group, #p < 










4.13. Hypothesis: correlation between Parkinson’s disease 
prevalence, consumption of certain antibiotics and gut microbial 
dysbiosis 
Systemic antibiotics significantly affect the microbiome resulting chronic dysbiosis in 
the gut, which may contribute to pathogenesis of neurological diseases. For instance, 
Parkinson’s disease (PD) is often associated with gastrointestinal symptoms. Gut 
dysbiosis in PD favors curli-producing Enterobacteria. Curli is a bacterial α-synuclein 
(αSyn) which is deposited first in the enteric nervous system and amyloid deposits are 
propagated in a prion like manner to the central nervous system. In addition, antibiotics 
result in a low-grade systemic inflammation, which also contributes to damage of neurons 
in enteric- and central nervous system. We tested the hypothesis whether consumption of 
different groups of antibiotics, belonging to four major groups (penicillin /J01C/, 
cephalosporin /J01D/, quinolones /J01M/, macrolides /J01F/) is associated with the 
change of Parkinson’s disease (PD) prevalence in different European countries [100]. 
Significant positive correlation (r=0.537, p=0.002) was found between the consumption 
of narrow spectrum + penicillinase (β-lactamase) resistant penicillin (J01CE+J01CF) and 
the increased prevalence of PD (Fig. 34). The geographical distribution of the correlation 
is also worth of mentioning (Fig.34). While the correlation was strong in the Scandinavian 
countries (Denmark, Sweden and Norway), it is also interesting to note, that PD 











Figure 34. Correlation between consumption of certain penicillins and prevalence of 
Parkinson’s disease.  
Consumption of narrow spectrum β-lactamase sensitive (J01CE) and β-lactamase 
resistant penicillins is expressed in DID (DID=Defined Daily Dose (DDD)/1000 
Inhabitants/Day) [103]. 
 
Figure 35. Chart indicating penicillin consumption in different European Union (EU) 
countries (ESAC project).  
Penicillin consumption is expressed in DID. DID is the Defined Daily Dose (DDD)/1000 
Inhabitants/Day. Countries marked with green arrows consume the highest amount of 
narrow spectrum penicillin (green) and β-lactamase resistant penicillin (blue) within 





5.1. The effect of acute stress and effect of the activation of 
CRHPVN on metabolic system 
The hypothalamic paraventricular nucleus harbors neurons that integrate 
neurondocrine, autonomic and behavioral responses to stress. These, functionally distinct 
cell types are spatially distributed in the rat hypothalamus, however are intermingled 
within the pareventricular region in case of mice and human [104]. 
It is well established that hypophyseotropic neurons of the PVN initiate the 
neuroendocrine stress cascade, while autonomic parvocellular neurons of the PVN that 
project to the brain stem and spinal cord are preganglionic cells of the sympathetic 
nervous system. Activation of the sympatho-medullary and sympatho-adrenal systems all 
involved in recruitment of bodily resources to “fight or flight” responses. While the 
neuronal circuits regulating HPA axis activity are well described, much less is known 
about the means with which stress-induced metabolic and behavioral responses are 
organized.   
Fight or flight- either stress-coping strategies require energy. Only a few studies 
addressed directly metabolic changes accompanying acute or chronic stress. Here we 
have shown that acute restraint stress results in a significant elevation of energy 
expenditure in the first four hours post-stress and in the light (passive) phase of the 
circadian rhythm 12h later. The first 4h time window for special detailed metabolic 
analysis has been selected because most of the acute stress-induced hormonal changes 
and neuronal activation occur in this time frame. Our results are in agreement with 
previous findings on stress-induced elevation of energy expenditure in mice exposed to 
tail suspension stress [105]. By contrast, Spiers et al. did not detect significant changes in 
energy expenditure of male mice restrained for 2 hours [106]. These authors however, 
analyzed the whole 96h post-stress data together.  
Hormonal stress mediators (adrenaline, noradrenaline and glucocorticoids) have 
profound effect on energy metabolism. Adrenaline increases blood glucose concentration 
via stimulation of hepatic glucose production and inhibition of glucose disposal in insulin-
dependent tissues [107]. Adrenaline boosts lipolysis in the white adipose tissue and 
activates uncoupling protein UCP-1-mediated thermogenesis in the brown adipose tissue 




Stress-induced level of corticosteroids results in hyperglycaemia via increased 
gluconeogenesis in the liver, and impaired glucose uptake efficiency [109]. Excess 
glucocorticoids decreases of fat depots and elevates circulating fatty acid through 
increased hydrolysis of circulating triglycerides by activation of lipoprotein lipase. 
Furthermore, glucocorticoids also increase de novo lipid production in hepatocytes 
through increased expression of fatty acid synthase [110].  
Based on the complex effects of major stress-mediators on the energy metabolism, it 
is very likely that the energy consumed during acute stress response originates 
predominantly from fatty acid oxidation. However, this is not supported by the respiratory 
exchange ratio data obtained in our study. Although RER values of acutely restrained 
mice are below of that of the non-stressed controls throughout the whole circadian cycle 
post-stress, the difference from the control measurement is not significant.  
The acute stress-induced energy expenditure correlates with the increased activity of 
mice especially in the first couple of hours after releasing mice from the restrainers. Using 
an automated video and vibration behavioral analysis system („Behavioral 
Spectrometer”), Brodkin et al. detected dramatic changes in behavior of stressed 
mice. There were large increases in grooming of all body parts (i.e., paw, face, head, 
cheek, leg, back, and genitals) accompanied by a moderate increase in scratching. By 
contrast, restraint produced dramatic decreases in locomotion (walk and run) and a mild 
decrease in the orienting behaviors of sniff and survey [111]. Unfortunately, TSE 
Phenomaster, used in our studies, detects the sum of XYZ activities and can’t differentiate 
between distinct behavior elements. Nevertheless, it has been previously revealed that 
restraint and other psychogenic stressors increase grooming behavior shortly after stress 
[112] and therefore it is likely that early increases in activity seen in our acutely restrained 
mice might be due to grooming or rearing [113]. By contrast, activity following acute 
restraint stress, was significantly decreased in the dark phase of circadian rhythm. This, 
delayed and sustained reduction of locomotor activity has been reported in previous 
studies [106, 111, 114]. 
Reduced activity following stress may serve to replenish depleted energy stores. This 
is supported by increased food intake seen in the fourth hour post stress, two hours after 
the peak of energy expenditure. Stress-eating is a well-known behavior and conserved 
across species. Both humans and laboratory rodents have been shown to increase their 
food intake following stress or negative emotions [115, 116]. Furthermore, stressed 




glucocorticoids are key factors for responding to reduced energy stores. They increase 
food intake and alter food choice [118].  
Corticotropin-releasing hormone, CRH plays an important role in food choice and 
activity. Expression of this neuropeptide rapidly increases after stress not only in the 
hypothalamic paraventricular nucleus but in other brain regions involved in stress 
regulation [108]. CRH and other members of it’s family of neuropeptides (urocortin 
1,2,3) have significant anorexigenic and thermogenic activities [119]. Furthermore, 
centrally administered CRH increases physical locomotor activity. Eavens et al., 
demonstrated that CRH increases locomotor activity independently of pituitary hormone 
secretion, since CRH induced locomotor activity was seen  in hypophysectomised 
following intracerebroventricular (icv) administration of in dose dependent manner rats 
[120]. Coincident data was revealed by Lowry et al. reporting that CRF antagonist α-
helical CRF9–41 (ahCRF) reduced stress induced locomotor activity in dose dependent 
manner [121].  
To identify if CRH neurons in the hypothalamic paraventricular nucleus are involved 
in stress-related metabolic and activity responses, we have used a chemogenetic 
approach. Using CRH-IRES-Cre mice (on the same C57BL6 background as in metabolic 
experiments), we have challenged CRHPVN neurons and recorded metabolic parameters 
and physical activity. Previous studies from our laboratory confirmed that selective 
activation of CRHPVN neurons results in plasma CORT elevation similar to that seen in 
response to acute stress. Hormonal assessment also indicated that the effect of neuronal 
activation following chemogenetic activation lasts longer (up to 4-5h) than an acute 
stress, however the peak CORT levels are comparable. Chemogenetic activation of 
CRHPVN neurons recapitulates some, but not all metabolic markers seen after acute 
restraint. Energy expenditure is increased during the first 4 hours after CNO injection, 
similar to that seen in restrained mice, however the second peak in the next day light 
phase was not detected. Food intake was the other marker that showed similarities 
between acutely stressed animals and following chemogenetic activation of CRHPVN 
cells. In both cases, cumulative food intake was increased. There were differences, 
however, in the timing. Following acute restraint stress, food intake gradually increased 
post-stress and became significant by the fourth hour, while it was promptly elevated after 
CNO injection and remained on a plato in chemogenetically chellenged mice. Neither 





We could not detect over changes in locomotor activity following CNO administration 
to CRH-IRES-Cre mice with pAAV-hSyn-DIO-hM3D(Gq)-mCherry injection into the 
PVN. These results underscore the importance of relevant control experiments and 
highlight the drawback of CNO as an activator of DREADD receptors. When 
CRH_IRES-Cre mice were injected with control virus construct into the PVN, we 
detected decreased locomotor activity following CNO injection. Recent pharmacokinetic 
analysis demonstrated CNO reverse-metabolization to its parent compound clozapine in 
mice and rats, yielding plasma concentrations that may be sufficient to occupy inter alia 
dopamine D2/3 and serotonin 5HT2A receptors in the brain. Clozapine is an antipsychotic 
drug, which is widely used for schizophrenia treatment. The drug is an effective agonist 
at GABAB receptor and the GABAB receptor deficient mice exhibit altered locomotor 
behaviour [122, 123]. For these reasons, the authors of the pharmacological study of CNO 
propose the use of appropriate control groups and appropriate DREADD activating drug 
with which we can avoid its side effects [124]. 
It is very likely, that the CNO counteracts with the effects of CRHPVN on locomotion. 
Indeed, optogenetic silencing of CRHPVN neurons resulted in reduced physical activity, 
grooming and rearing following foot shock stress indicating a stimulatory role of CRHPVN 
neurons in regulation of physical activity [125].  
It should also be noted, that we could not detect over changes of EE and RER values 
after CNO injected control animals, although clozapine has metabolic side effects [126].  
 
5.2. Metabolic changes after chronic stress and during recovery 
Acute stress response is a short term adaptation process to environmental stimuli. This 
short term adaptation could even be beneficial and increase resilience. However, 
continuous stress load may result in both physical and emotional health problems over 
time. During chronic stress, the permanently increased glucocorticoid level keeps the 
blood glucose level high, as we have confirmed in the two-hits protocol, and these effects 
are associated with elevated insulin level leading to insulin resistance and diabetes 
mellitus [127]. Fat mobilizing effects of glucocorticoids and catecholamines are also 
dominant in chronic stress, that result elevated TG level and thus trigger the risk of 
hypertriglyceridemia, NAFLD or atherosclerosis [64].  
In our experiment, increased food intake was detected in chronically stressed mice, 




axis and it consequently influences energy intake and homeostasis. Chronic stress can 
impact on multiple appetite-related hormones and neuropeptids [128]. Release of 
hypothalamic CRF suppresses food intake [129, 130], in contrast, glucocorticoids 
stimulate appetite [131] and induce preference for consumption of palatable food [132]. 
However, the permanent elevated glucocorticoids suppress CRH release from PVN and 
vasopressin becomes the main regulator of ACTH secretion during chronic stress [133].   
Previous study indicated altered locomotor activity in mice, which were exposed to 
social defeat stress for 10 days [134]. Locomotion was decreased during chronic stress 
and it remained reduced for two days after stress. By contrast, increased locomotor 
activity was detected in our study after CVS, however it was induced significantly only 
during the resting phase. Similar to our study, Hiroshi Ito et al revealed hyper-locomotion 
activity after 7 days of chronic restraint stress. These changes associated with increased 
synaptic plasticity in the anterior cingulate cortex (ACC) by induced excitability because 
of the disruption of the inhibitory effect of GABAA receptor signaling pathway [135]. 
Another study compared the effect of chronic restraint and variable stress on locomotor 
behavior. Only chronic restraint stress altered locomotion, whereas chronic variable stress 
has no effect [136]. To conclude, these results confirm the assumption that chronic stress 
induced locomotor behavior changes probably highly influenced by the period and the 
severity of chronic stress. In addition, there is might be one concrete explanation to this 
result, which underlines the increased locomotion during resting state. Previous studies 
indicated, glucocorticoid administration increases wakefulness and induces reduction of 
REM sleep [137, 138]. 
The permanent presence of stressful stimuli during chronic stress is accompanied with 
continuous homeostatic adaptation, which demands energy. These processes constantly 
activate the sympathetic nerve system and HPA axis, thus, catabolic pathways are 
activated predominantly through the effects of glucocorticoids and catecholamines [139]. 
In addition, UCP1 expression is stimulated by the sympathetic nervous system in brown 
adipose tissue and thus, stress induces hyperthermia [140]. All these changes 
consequently lead to increased energy expenditure. Therefore, not surprisingly, elevated 
energy expenditure of the stressed mice was detected after CVS.  
Respiratory exchange ratio was also higher in the stressed mice, which suggest that 
carbohydrate utilization was rather preferred to support energy expenditure. Besides the 
carbohydrate utilization, interestingly, higher lean and lower fat mass were measured by 




of the increased locomotor activity. A possible explanation of the lower fat mass is might 
be the glucocorticoid effect on GLUT4 membrane protein. In a previous study, alleviated 
level of GLUT4 expression was observed in fat cells but it was induced in skeletal muscle 
after administration of dexamethasone or with the concomitant injection of sucrose [141]. 
Accordingly of this result, GLUT4 could decrease glucose transport into adipocyte and 
this effect accompanied with reduced adipose tissue [142]. In contrast, glucose transport 
would be increased into the enlarged skeletal muscle tissue and thus the preference for 
utilization of carbohydrates would increase.  
Next, we have been interested how the metabolic homeostasis recovers after chronic 
stress. Although a short recovery period was selected, in a previous study indicated that 
2 weeks of visible burrow system (VBS) model of chronic stress increased corticosterone 
level, which returned to the control level after one week. Furthermore, the reduced body 
weight of subordinate and dominant rats increased continuously during recovery but only 
the body weight of dominant mice restored to the control level, whereas the body weight 
of the subordinate mice reminds significantly lower even three weeks after VBS 
compared to the control group. These changes were associated with increased food intake, 
fat and lean mass gain during the three weeks of recovery [143]. Previous studies 
indicated other restorable effects in hippocampus. Three weeks of chronic stress induced 
impaired spatial working, reference memory and retracted CA3 dendrites were reversible 
after 3 weeks of recovery [144]. Lin M. et al indicated restoration of behavioral 
impairment and the alteration in the glutamate receptor expression to the normal level 
after 35 days of recovery [145]. Within the hippocampus, another important hub of stress 
regulation, Gray J. D. and colleagues identified 700 genes differentially expressed in 
chronically stressed animals compared to non-stressed controls. 21 days of resting period 
hippocampal gene expression was compared again and found an additional 700 genes to 
be differently expressed, however only 36 genes overlapped between the stressed and 
rested animals [146]. Another study revealed that recovery time of the immune system is 
highly dependent from the severity of the stressor. In this study, rats were exposed to 
daily restraint stress for 2, 4 and 8 weeks followed by 6 weeks of recovery and the results 
showed that the longer exposure time of the stress the higher of the immune system 
damage, whereas shorter exposure time shortened the recovery time [147]. In spite of 
these results, glucocorticoid levels seems to be independent from the severity of the stress 
during recovery. Ottenweller J. E. et al demonstrated that 10, 7, 4 and 3 days footshock 




exposure time has no effect on the glucocorticoid level reduction during three days of 
recovery [148]. In addition, X. Mengyang and colleagues indicated the reversibility of 
the microbial changes after three weeks of recovery, in spite of the restored microbiome, 
the difference of the microbial metabolites was more persistent, it was still detectable 
three weeks after the end of stress [149]. In our study, the most striking results were the 
body composition changes. Beside increased body weight, restored fat and lean mass 
level were measured after three days of recovery. In the other metabolic parameters, only 
a decreasing tendency was measured, except for the energy expenditure changes during 
the active phase, where significant reduction was observed after three days of recovery. 
The conclusion of these data, most of the chronic stress induced changes are reversible, 
however the reversibility time depends on different parameters like exposure time, 
recovery time and severity of stressor, etc. 
 
5.3. Chronic stress effect on colon microbiome and gut 
There is a well-documented mutual interaction between the gut microbiome and host 
stress response [150, 151]. Chronic stress is an important environmental factor, which 
triggers gut dysbiosis and in turn, altered microbiome has an impact on neuroendocrine- 
autonomic and behavioral aspects of the stress response. Growing evidence indicates a 
link between stress and microbial dysbiosis [150, 152, 153]. Previous studies from 
different laboratories revealed distinct stress-induced changes of the gut microbiome 
composition depending on the stressor (water avoidance [154, 155] repeated restraint 
[156], social defeat/disruption [157-159] and origin of bacterial sampling (fecal [160], 
luminal [161] mucosal [162]. General conclusion of these studies is that chronic 
psychological stress results in outgrowth of Bacteroidetes and decrease the abundance of 
Firmicutes. Here we confirm and extend these observations to show that MS-CVS “two 
hits” paradigm is also capable to increase Bacteroidetes and Proteobacteria in chronically 
stressed mice, which is accompanied here with an overall decrease of total bacterial DNA 
concentration in the colon content.  
A number of studies have identified early life adversity as an important factor affecting 
gut microbiome [163]. Studies in rats, mice and Rhesus monkeys revealed decrease of 
microbial diversity following maternal separation [164] or limited nesting [165]. Here, 




maternal separation and chronic variable stress paradigm, both of which might have an 
impact on gut microbiome.  
Among the bacterial species studied here, the copy number of Clostridia increased 
significantly as a result of MS-CVS stress paradigm. This finding is in agreement with 
those of [157, 166]. Although some Clostridia are pathogenic and are responsible for 
diarrhea in the elderly, we did not observe serious diarrhea or watery feces in our stressed 
mice.  
“Leaky gut” is generally held as a hallmark of chronic stress-related pathologies [167, 
168]. In the present MS-CVS model we did not detect stress-induced changes in colonic 
expression of tight junction proteins (Occludin, TJP1-3) and muc2. However, we did find 
significant decrease of mucosa thickness, signs of epithelial damage. Furthermore, 
increased transcellular transport was detected in the gut of chronically stressed mice by 
FITC-dextran method, indicating impaired barrier function [169]. The leaky barrier 
should allow various feed/microbiome related antigens to initiate local immune 
responses. Such an innate immune activation has been revealed by infiltration of F4/80 
positive macrophages into the lamina propria of MS-CVS exposed mice, which was 
prevented by rifaximin treatment during chronic variable stress. Gut lymphatics are 
drained in mesenteric lymph nodes (MLN), where a significant bacterial load has been 
revealed in our chronically stressed mice. This finding is compatible with the report by 
Velin et al. [170] where 30 times increased E coli passage was detected in chronically 
stressed rats, ex vivo. In addition to this local bacterial translocation to MLN, significant 
elevation of LPS was detected in the plasma of MS-CVS mice, indicating systemic 
endotoxemia.  
Another noteworthy finding of this study is the stress-induced colonic upregulation of 
Reg3b. Reg3b is a C-type lectin, which belongs to antimicrobial peptide (AMP) family 
and involved in gut barrier functions [171]. Further studies are required to clarify if 
increased expression of Reg3b mRNA may represent an adaptive compensatory host 
mechanism to impaired barrier and increased bacterial burden 
Chronic stress exposure is a risk factor for psychiatric disorders, such as anxiety and 
depression, subsets of which are accompanied or driven by activated immune system 
[172, 173]. Parallel to stress-induced microbiome changes, chronic stress increases gut 
permeability and results in a leaky gut, through which bacterial cell wall components 




systemic inflammation. LPS and related proinflammatory cytokines activate the HPA 
axis [174] and promote deterioration of stress-induced anxiety [175]. 
In search for the causal role of microbiome in the development of stress-related 
psychopathologies, Langgartner et al. showed that stress-induced psychobiological 
changes can be transmitted by fecal transplantation from stressed to non-stressed mice 
[158]. In contrary, our present results suggest that settlement of stress-induced changes 
in the gut does not alleviate MS-CVS-induced locomotor hyperactivity, anxiety-like 
symptoms in open field and elevated plus maze tests and anhedonia. One explanation for 
the resistance of stress-induced behavior to improvement of gut and immune functions 
would be the timing of rifaximin treatment. It is likely that behavior needs more time than 
gut to recover from CVS. Another possibility would be that early life adversity i.e. 
maternal separation results in permanent changes in the gut flora [163] and behavior, 
which do not change after antibiotic treatment in the adulthood. Indeed, it has been shown 
that early life events result in epigenetic modulation of stress/anxiety-related genes such 
as hypomethylation of the Crh promoter in the PVN of maternally deprived adult rats 
[176] and reduction in histone H3 acetylation at human/rat glucocorticoid receptor (GR, 
NR3C1) promoter in the hippocampus [177].  
5.4. Antibiotic effect on gut microbiome 
Among the factors, influencing the gut microbiome, antibiotic exposure has profound 
and sometimes persisting impact on the bacterial composition, diversity and function of 
the intestinal flora [178]. In addition to the use antibiotics for medical reasons, the human 
body is unintentionally exposed to antibiotics present in feeds and in the environment. 
Animal husbandry use subtherapeutic dose of different antibiotics to increase the growth 
rate and feed efficiency, as well as for disease prevention in overcrowded locations 
including aquacultures [179-181]. Antibiotics decrease the microbial diversity of the gut 
flora, modulate Bacteroidetes/Firmicutes ratio and result in overgrowth of opportunistic 
pathogens [182, 183]. For instance, a 7-day treatment with commonly used antibiotic 
groups: fluoroquinolones and β-lactams, significantly decreased microbial diversity by 
25% and reduced the core phylogenetic microbiota from 29 to 12 taxa [184, 185]. Another 
recent study on healthy subjects, found an immediate bloom of Enterobacteria and other 
pathobionts along with significant depletion of Bifidobacteria and butyrate-producing 
species in response to a meropenem, gentamicin and vancomycin cocktail. Although the 




some common species, which were present in all subjects before the treatment, remained 
undetectable after 4 months [186].  
There is a general agreement in the literature that, apart from genetic background, PD 
is caused by some external effect and the primary change leading to the disease is the 
modified gut flora, dysbiosis. Even the suspected toxic agents, like pesticides, operate 
through the altered microbiome in the process of developing PD. Considering the fact that 
antibiotics are powerful agents influencing the microbiome, it is likely that some 
penicillins, as “external factors” initiate gut dysbiosis, which contribute to the 
development of PD. Our study compared global antibiotic consumption to the change of 
PD prevalence in different European countries in the past 25 years might provide some 
clues elucidating the issue [100]. To support our hypothesis, a recent work evaluated the 
impact of antibiotic exposure on the risk of PD in a register-based case- control study in 
Finland. This study also found significant association between exposure to certain types 
of oral antibiotics and increased risk of PD, with a delay that is consistent with the 
proposed duration of a prodromal period [187]. Our findings show connection between 
high consumption of narrow spectrum penicillin and the highest prevalence change of 
PD. Two major mechanisms may underlie the connection between exposure of certain 
antibiotics and increased prevalence of PD: First, antibiotics induce gut dysbiosis, a 
microbial imbalance, in which certain curly- producing bacteria gain abundance in the 
microbiome. Curly, as a functional α-synuclein (αSyn), excreted to the extracellular space 
and exaggerates additional amyloid deposition. The αSyn pathology has the ability to 
spread from the gastrointestinal tract to the brain and results in loss of vulnerable 
dopamine synthesizing neurons in the substantia nigra. Second, these antibiotics may 
promote inflammation, via translocation of live gut bacteria and inhibition of anti-
inflammatory, short chain fatty acid (SCFA) (butyrate)-producing bacteria. Systemic 
inflammation in general-, and local neuroinflammation (microglia activation), in special-
, contribute to PD pathogenesis. 
Rifaximin, which is a non-absorbable antibiotic, specifically targets Clostridia and 
other Gram negative and positive bacteria. Therefore, we hypothesized that rifaximin 
treatment of mice exposed to MS-CVS will restore microbiome related gut-brain axis and 
behavioral changes to normal. Indeed, stress-induced Clostridia were significantly 
attenuated by antibiotic treatment. In addition, rifaximin administration prevented stress-
induced increases of Proteobacteria, but not Bacteroidetes. These data confirm previous 




fecal microbiome [188] and only mild changes are observed in mice [189]. More recently, 
rifaximin was recommended for treatment of post-infectious irritable bowel disease (IBS) 
and related abdominal discomfort [190, 191]. In search for the mechanism of rifaximin 
action, increased expression of gut tight junction proteins emerged [189]. We have 
confirmed increased mRNA levels of tight junction proteins occludin, tjp1 and tjp2, but 
not tjp3, in colon samples of stressed and non-stressed, rifaximin treated mice. Increased 
expression of tight junction proteins along with slightly increased muc2 indicates 
improved gut barrier function after rifaximin administration.   
Rifaximin administration during CVS prevented the increase of LPS plasma levels, 
suggesting that rifaximin effects go beyond anti-pathogenic activity. The endotoxemia 
reducing effects of rifaximin has already been shown in chronic liver disease [192]; 
however, the mechanisms of action and molecular targets remain unknown.  
Finally, rifaximin reduced pathogenic bacteria and improved gut barrier, however, did 
not enforce the abundance of beneficial “psychobiotic” bacteria. It has been shown that 
administration of certain Lactobacilli and Bifidobacteria have anxiolytic/antidepressive 
effects [193-195].  
Recent studies implicate that antibiotic usage in human and farm animals results in 
dysbiosis, provoke systemic inflammation, which might be responsible for long-term 
metabolic- (obesity), behavioral- and mental changes. However, we did not detect any 
significant behavioral changes in unstressed mice treated with antibiotic for 3 weeks. 
Future work should focus on the interaction between systemic antibiotics and stress in 
regulation of microbiota-gut-brain axis.  
In conclusion, combination of early life adversity with adult chronic variable stress 
(CVS) paradigm in mice results in gut dysbiosis and impaired gut barrier function along 
with increased locomotor activity, anxiety-like behavior and neophobia. Rifaximin 
treatment during CVS decreases stress-induced pathogenic bacteria, restores gut barrier 
functions, reduces local and systemic bacterial load, however, does not improve stress-









The main conclusion of my dissertation are: 
1. Acute psychogenic stress has profound effect on the metabolic parameters, energy 
expenditure and food intake as well as on locomotor activity. 
2. The hypothalamic paraventruclar nucleus is a part of a neuronal circuit, which 
mediates acute stress effects on metabolism and activity. 
3. Chronic stress results in lasting changes of body composition and metabolism, 
with increased food intake, energy expenditure and respiratory exchange ratio. 
These chronic stress-induced alterations recover differently after cessation of the 
challenge. 
4. Chronic stress results in gut dysbiosis, increased gut permeability and recruitment 
of activated macrophages in the colonic mucosa. 
5. Rifaximin -a gut specific antibiotic- restores stress-induced changes in gut 
microbiome, gut permeability and bacterial load, however these positive changes 
in the gut are not accompanied by restoration of normal behavior. 
6. Gut dysbiosis following systemic antibiotic treatment might be a risk factor in the 



















Stress is a non-specific adaptation reaction from the body to different environmental 
changes. The response triggers various complex mechanisms in which the metabolic 
system is also involved. The activation of the HPA axis demand high energy requirement. 
Thus, chronic stress, which is a permanent long lasting process, can provoke various 
metabolic related maladaptive diseases. In contrast, simple acute stress is rapid response, 
which can be even beneficial. In addition, it is well established, chronic stress induces 
“leaky gut” syndrome and dysbiosis in the gut microbiome and thus, it further aggravates 
the chronic stress induced maladaptive process like neuronal or behavioral impairments. 
In this current dissertation, we examined the metabolic changes after the activation of 
HPA axis by acute stress or potentiation of CRH neurons in PVN. We also observed the 
effect of chronic stress and recovery on metabolic system. In addition, we investigated 
antibiotic effect during chronic stress on behavior and colon physiogy; and its correlation 
with Parkinson’s disease (PD).  
Acute stress has a short-term effect on locomotion and food intake. Whereas, energy 
expenditure was affected for a long-term. These changes were accompanied with dropped 
body weight and fat mass. The activation of CRHPVN neurons similarly influenced 
metabolic system as acute stress, however, there were also differences. Long-term effect 
of HPA activation was not seen and the food intake behavior was different in the first 
four hours. Chronic stress evoked robust changes in metabolic system and slight alteration 
was seen after three days of recovery. Two hits paradigm stress induced dysbiosis in gut 
microbiome. In addition, we found extenuation of colonic mucosa, increased bacterial 
translocation to mesenteric lymph node, elevation of plasma LPS levels and infiltration 
of F4/80 positive macrophages into the colon lamina propria. Chronically stressed mice 
displayed anxiety-like behavior and neophobia. Rifaximin treatment decreased 
Clostridium concentration, gut permeability and LPS plasma concentration and increased 
colonic expression of tight junction proteins (TJP1,TJP2) and occludin. However, these 
beneficial effects of rifaximin in chronically stressed mice was not accompanied by 
positive changes in behavior. Finally, significant correlation was calculated between 
antibiotic consumption and PD prevalence.  
These findings emphasized the role of metabolic system after stress and help to 
understand the development of different stress induced metabolic related diseases and the 





A stressz egy adaptációs válasz folyamat, különböző környezeti változások hatására. 
A válaszreakció során különböző mechanizmusok indukálódnak, amelyek rengeteg 
energiát igényelnek, ezért a metabolikus rendszernek kiemelt szerepe van a stressz során. 
A stressz időbeli lefolyása alapján megkülönböztetünk akut és krónikus stresszt. Számos 
tanulmány bizonyította már, hogy a folyamatos stressz jelenléte diszbiózist eredményez 
a bél mikrobiomban és gerjeszti a bél átjárhatóságát, amely tovább súlyosbítja különböző 
maladaptív folyamatok hatását. 
Disszertációmban a stressz indukálta metabolikus változásokat vizsgáltuk akut 
stressz után illetve, a CRH neuronoknak milyen szerepe van ezekben a változásokban. 
Továbbá tanulmányoztuk a metabolikus változásokat krónikus stresszt követően és a 
felépülés alatt is. Valamint vizsgáltuk a krónikus stressz során az antibiotikus hatást a 
viselkedésre, a vastagbél fiziológiájára és az antibiotikum fogyasztás korrelációját a 
Parkinson-kór prevalenciájával (PD). 
Az akut stressz a lokomotoros aktivitást a táplálékfelvételt és az energia felhasználást 
indukálja. A CRHPVN neuronok aktiválásával hasonló metabolikus változásokat 
indukáltunk, mint az akut stressz során. Azonban különbségeket is meg lehetett figyelni. 
Az emelkedett energiafelhasználás hosszú távon nem volt megfigyelhető és a 
táplálékfelvétel eltérő volt az első négy órában. A krónikus stressznek jelentős hatása volt 
a metabolikus rendszerre és a három napos felépülés után enyhe csökkenést lehetett csak 
megfigyelni. A két csapás stressz paradigma diszbiozist idézett elő a vastagbél 
mikrobiomájában. Ezenk,ívül a vastagbél nyálkahártyája elvékonyodott, megnövekedett 
a bakteriálistranszlokáció a mesenteriális nyirokcsomókban, a plazma LPS szintje 
szignifikánsan magasabb volt, megnövekedett az F4 / 80 pozitív makrofágok száma a 
lamina propria-ban és a krónikus stressz szorongásos viselkedést és neophobiát váltott ki. 
Egy nem felszívódó antibiotikum kezelés (rifaximin) hatására helyre tudtuk állítani a 
mikrobiom diszbiózist és a krónikus stressz indukálta változásokat a vastagbélben. 
Azonban a viselkedésbeli változásokra nem volt hatással.  
Ezek az eredmények a metabolikus rendszer stresszben betöltött szerepét emelik ki, és 
segítenek megérteni a metabolizmussal kapcsolatos stressz indukálta betegségek 
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